"[{\"model\": \"drug.drug\", \"pk\": \"DB00209\", \"fields\": {\"drugtype\": 1, \"name\": \"Trospium\", \"groups\": \"0\", \"categories\": \"183\", \"description\": \"Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably.[L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination.[L6208]  Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211]\", \"aliases\": \"Jamp Trospium|Sanctura|Trospium Chloride|Sanctura XR|Trospium Chloride ER|Mar-trospium|Trospium|Accel-trospium|\\n      |Trosec\", \"superclass\": \"9\", \"classname\": \"26\", \"subclass\": \"38\", \"direct_parent\": \"74\", \"indication\": \"For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.\", \"pharmacodynamics\": \"Trospium is an antispasmodic, antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. According to receptor assays, it displays higher affinity towards muscarininc receptors compared to nicotinic receptors at therapeutic concentrations. \", \"moa\": \"Trospium antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder.\", \"absorption\": \"9.6%\", \"toxicity\": \"None\", \"halflife\": \"20 hours\", \"distribution_volume\": \"* 395 \u00c2\u00b1 140 L\", \"protein_binding\": \"50-85%\", \"dosages\": \"[('', 'Oral'), ('20 mg/1', 'Oral'), ('60 mg/1', 'Oral'), ('15 MG', 'Oral'), ('30 MG', 'Oral'), ('15 mg', 'Oral'), ('20 MG', 'Oral'), ('30 mg', 'Oral'), ('45 MG', 'Oral'), ('20 mg', 'Oral'), ('10 MG', 'Oral'), ('5 MG', 'Oral'), ('20 mg', 'Oral'), ('30 MG', 'Oral'), ('5 MG', 'Oral'), ('20 mg/1', 'Oral'), ('60 mg/1', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('60 mg', 'Oral'), ('20 mg', 'Oral')]\", \"properties\": \"[('logP', '2.86'), ('logS', '-6.8'), ('Water Solubility', '6.68e-05 g/l'), ('logP', '-0.5'), ('IUPAC Name', \\\"(1S,3R,5R)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-8\u00ce\u00bb\u00e2\u0081\u00b5-azaspiro[bicyclo[3.2.1]octane-8,1'-pyrrolidin]-8-ylium\\\"), ('Traditional IUPAC Name', 'trospium'), ('Molecular Weight', '392.518'), ('Monoisotopic Weight', '392.22202025'), ('SMILES', '[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1'), ('Molecular Formula', 'C25H30NO3'), ('InChI', 'InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1/t21-,22+,23+'), ('InChIKey', 'OYYDSUSKLWTMMQ-JKHIJQBDSA-N'), ('Polar Surface Area (PSA)', '46.53'), ('Refractivity', '124.04'), ('Polarizability', '43.25'), ('Rotatable Bond Count', '5'), ('H Bond Acceptor Count', '2'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '11.05'), ('pKa (strongest basic)', '-4.5'), ('Physiological Charge', '1'), ('Number of Rings', '5'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '0'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"172\", \"pubChemCompound\": \"102\", \"pubChemSubstance\": \"188\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB00219\", \"fields\": {\"drugtype\": 1, \"name\": \"Oxyphenonium\", \"groups\": \"0\", \"categories\": \"193\", \"description\": \"A quaternary ammonium anticholinergic agent with peripheral side effects similar to those of atropine. It is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect. [PubChem]\", \"aliases\": \"\\n      |Oxyphenonium\", \"superclass\": \"9\", \"classname\": \"26\", \"subclass\": \"1\", \"direct_parent\": \"80\", \"indication\": \"For the treatment of visceral spasms\", \"pharmacodynamics\": \"Oxyphenonium is an anticholinergic drug, a medication that reduces the effect of acetylcholine, a chemical released from nerves that stimulates muscles, by blocking the receptors for acetylcholine on smooth muscle (a type of muscle). It also has a direct relaxing effect on smooth muscle. Oxyphenonium is used to treat or prevent spasm in the muscles of the gastrointestinal tract in the irritable bowel syndrome. In addition, Oxyphenonium inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions.\", \"moa\": \"Action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic).\", \"absorption\": \"None\", \"toxicity\": \"None\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"93% bound to albumin\", \"dosages\": \"[]\", \"properties\": \"[('logP', '0.2'), ('logS', '-6.4'), ('Water Solubility', '1.36e-04 g/l'), ('logP', '-0.2'), ('IUPAC Name', '{2-[(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxy]ethyl}diethylmethylazanium'), ('Traditional IUPAC Name', 'methacin'), ('Molecular Weight', '348.4996'), ('Monoisotopic Weight', '348.253868959'), ('SMILES', 'CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1'), ('Molecular Formula', 'C21H34NO3'), ('InChI', 'InChI=1S/C21H34NO3/c1-4-22(3,5-2)16-17-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6,8-9,12-13,19,24H,4-5,7,10-11,14-17H2,1-3H3/q+1'), ('InChIKey', 'GFRUPHOKLBPHTQ-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '46.53'), ('Refractivity', '112.61'), ('Polarizability', '40.65'), ('Rotatable Bond Count', '9'), ('H Bond Acceptor Count', '2'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '11.53'), ('pKa (strongest basic)', '-4.3'), ('Physiological Charge', '1'), ('Number of Rings', '2'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"182\", \"pubChemCompound\": \"112\", \"pubChemSubstance\": \"198\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB00424\", \"fields\": {\"drugtype\": 1, \"name\": \"Hyoscyamine\", \"groups\": \"0\", \"categories\": \"377\", \"description\": \"Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine].[A228423] It is commonly extracted from plants in the _Solanaceae_ or nightshade family.[A228423] Research into the action of hyoscyamine in published literature dates back to 1826.[A228713] Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimuscarinic properties.[L31548,L31553]\\r\\n\\r\\nAlthough hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553]\", \"aliases\": \"Pyrelle H.B.|Hyosyne|Urolet Mb|Levsin SL|Phenobarbital with Belladonna Alkaloids - Grape|Urimar-T|Uta|Donnatal Tab|PB Hyos|Phosphasal|Hyoscyamine Sulfate TAB|Uribel|Donnatal Elixir|Belladonna Alkaloids with Phenobartbital|HyoMax-DT|Belladonna Alkaloids with Phenobarbital|Vilamit MB|Hyoscyamine S L|Symax SR|Re-PB Hyos Elixir|Phenobarbital with Belladonna Alkaloids|Darpaz|Donnatal Extentabs|Urin D/S|Hyolev Mb|Levsin Drops 0.125mg/ml|Indiomin Mb|Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate and Scopolamine Hydrobromide|Hyoscyamine Sulfate Sublingual|Uro-BLUE|Hyoscyamine Sulfate Sl|Uro-L|Symax SL|Urogesic Blue|Phenazopyridine Hydrochloride, Hyoscyamine Hydrobromide, and Butabarbital|Hyoscyamine Sulfate|Urised|Anaspaz|Phenohytro|Me NaPhos MB Hyo 1|Symax Duotab|UroAv-81|Me-PB-Hyos|UroAv-B|Vilevev MB|Levsin|Urelle|Darcalma|B-Donna|UR N-C Urinary Antiseptic|Utira-C|Uro-MP|Hyoscyamine ER|Azuphen Mb|Vitetal|Donnatal Extentabs Srt|Hyoscyamine Sulfate Drops|HyoMax|Hyoscyamine SL|Ustell|Phenobarbital with Belladonna Alkaloids - Mint|Hyophen|Se-donna Pb Hyos|Donnagel Liq|HyoMax-SL|Hyoscyamine Sulfate Extended-Release|Phenobarbital With Belladonna Alkaloids|Oscimin|Diban Cap|Symax FasTab|Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide|Hyoscyamine|Phosenamine|HyoMax-FT|NuLev|Re-PB Hyos|Phenazopyridine Plus|Donnatal|Hyoscyamine Sulfate SL|Ed-spaz|Methylphen|Urophen Mb|Uramit Mb|Uro-458|\\n      |Prosed/DS|Uralgic|Levbid|Calmitol Itching Relief Ont|Hyoscyamine Sulfate ODT|HyoMax-SR|Quadrapax|Servira\", \"superclass\": \"12\", \"classname\": \"63\", \"subclass\": \"1\", \"direct_parent\": \"147\", \"indication\": \"As a drug that is not FDA approved, hyscyamine has no official indications.[L31548,L31553] Intravenous hysocyamine has been used to reduce gastric motility, reduce pancreatic pain and secretions, to facilitate imaging of the gastrointestinal tract, treat anticholinesterase toxicity, treat certain cases of partial heart block, improve visualization of the kidneys, and for symptomatic relief of biliary and renal colic.[L31548] Intravenous hyoscyamine is also used pre-operatively to reduce secretions of the mouth and respiratory tract to facilitate intubation.[L31548] Oral hyoscyamine is used to treat functional intestinal disorders, for symptomatic relief of biliary and renal colic, and symptomatic relief of acute rhinitis.[L31553]\", \"pharmacodynamics\": \"Hyoscyamine is not FDA approved, and so it has not official indications.[L31548,L31553] However, it is used as an antimuscarinic agent in a number of treatments and therapies.[L31548,L31553] Hyoscyamine has a short duration of action as it may need to be given multiple times per day.[L31548,L31553] Patients should be counselled regarding the risks and signs of anticholinergic toxicity.[L31548,L31553]\", \"moa\": \"Hyoscyamine competitively and non-selectively antagonises muscarinic receptors in the smooth muscle, cardiac muscle, sino-atrial node, atrioventricular node, exocrine nodes, gastrointestinal tract, and respiratory tract.[A228613,L31548,L31553] Antagonism of muscarinic M1, M4, and M5 receptors in the central nervous system lead to cognitive impairment; antagonism of M2 in the sinoatrial and atrioventricular nodes leads to bradycardia and lowers contractility; and antagonism of M3 in smooth muscle results in reduced peristalsis, bladder contraction, salivary secretions, gastric secretions, bronchial secretions, sweating, increased bronchodilation, mydriasis, and cycloplegia.[A228613,A228623,A228633]\", \"absorption\": \"Hyoscyamine is completely absorbed by sublingual and oral routes, though exact data regarding the C<sub>max</sub>, T<sub>max</sub>, and AUC are not readily available.[L31548,L31553]\", \"toxicity\": \"Patients experiencing an overdose may present with headache, nausea, vomiting, dizziness, dry mouth, difficulty in swallowing, dilated pupils, blurred vision, urinary retention, hot dry and flushed skin, tachycardia, hypertension, hypotension, respiratory depression, CNS stimulation, fever, ataxia, excitation, lethargy, stupor, coma, and paralysis.[L31548,L31553] Patients should be treated with symptomatic and supportive therapy which may include emesis, gastric lavage, activated charcoal, artificial respiration, or intravenous [physostigmine].[A228423,L31548,L31553] Dialysis is expected to remove hyoscyamine sulfate from circulation.[L31548,L31553]\", \"halflife\": \"The half life of hyoscyamine is 3.5 hours.[L31548,L31553]\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('0.125 mg/1', 'Oral; Sublingual'), ('', 'Topical'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('.125 mg/1', 'Oral'), ('0.125 mg/5mL', 'Oral'), ('0.125 mg/1mL', 'Oral'), ('0.125 mg/1', 'Sublingual'), ('0.125 mg/5mL', 'Oral'), ('25 mg/1mL', 'Oral'), ('0.125 mg/1mL', 'Oral'), ('0.125 mg/1mL', 'Oral'), ('0.125 mg/1', 'Oral'), ('0.15 mg/1', 'Oral'), ('0.375 mg/1', 'Oral'), ('0.125 mg/1', 'Oral; Sublingual'), ('0.375 mg/1', 'Oral'), ('.375 mg/1', 'Oral'), ('0.125 mg/1', 'Oral'), ('0.125 mg/1', 'Sublingual'), ('0.125 mg/1', 'Oral'), ('0.5 mg/1mL', 'Subcutaneous'), ('0.125 mg', 'Oral'), ('0.125 mg / mL', 'Oral'), ('0.125 mg/1', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('0.375 mg/1', 'Oral'), ('', 'Oral')]\", \"properties\": \"[('logP', '1.57'), ('IUPAC Name', '(1R,3S,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl (2S)-3-hydroxy-2-phenylpropanoate'), ('Traditional IUPAC Name', 'disodium dexamethasone phosphate(2-)'), ('Molecular Weight', '289.3694'), ('Monoisotopic Weight', '289.167793607'), ('SMILES', 'CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1'), ('Molecular Formula', 'C17H23NO3'), ('InChI', 'InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16-/m1/s1'), ('InChIKey', 'RKUNBYITZUJHSG-FXUDXRNXSA-N'), ('Polar Surface Area (PSA)', '49.77'), ('Refractivity', '80.82'), ('Polarizability', '31.74'), ('Rotatable Bond Count', '5'), ('H Bond Acceptor Count', '3'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '15.15'), ('pKa (strongest basic)', '9.39'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"365\", \"pubChemCompound\": \"294\", \"pubChemSubstance\": \"382\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB00505\", \"fields\": {\"drugtype\": 1, \"name\": \"Tridihexethyl\", \"groups\": \"19\", \"categories\": \"452\", \"description\": \"Tridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. Tridihexethyl is an antimuscarinic, anticholinergic drug. Tridihexethyl is no longer available in the US market. \", \"aliases\": \"\\n      |Tridihexethyl\", \"superclass\": \"6\", \"classname\": \"10\", \"subclass\": \"10\", \"direct_parent\": \"170\", \"indication\": \"Used as an adjunct in the treatment of peptic ulcer disease and in Acquired nystagmus\", \"pharmacodynamics\": \"Tridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. Tridihexethyl is an antimuscarinic, anticholinergic drug.\", \"moa\": \"Tridihexethyl binds the muscarinic acetylcholine receptor. It may block all three types of muscarinic receptors including M-1 receptors in the CNS and ganglia, M-2 receptors in the heart (vagus) and M-3 receptors at the parasympathetic NEJ system. The muscarinic acetylcholine receptors mediate various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Tridihexethyl inhibits vagally mediated reflexes by antagonizing the action of acetylcholine. This in turn reduces the secretion of gastric acids in the stomach.\", \"absorption\": \"None\", \"toxicity\": \"None\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[]\", \"properties\": \"[('logP', '2.31'), ('logS', '-7.3'), ('Water Solubility', '1.68e-05 g/l'), ('logP', '0.29'), ('IUPAC Name', '(3-cyclohexyl-3-hydroxy-3-phenylpropyl)triethylazanium'), ('Traditional IUPAC Name', 'tridihexethyl'), ('Molecular Weight', '318.5166'), ('Monoisotopic Weight', '318.279689779'), ('SMILES', 'CC[N+](CC)(CC)CCC(O)(C1CCCCC1)C1=CC=CC=C1'), ('Molecular Formula', 'C21H36NO'), ('InChI', 'InChI=1S/C21H36NO/c1-4-22(5-2,6-3)18-17-21(23,19-13-9-7-10-14-19)20-15-11-8-12-16-20/h7,9-10,13-14,20,23H,4-6,8,11-12,15-18H2,1-3H3/q+1'), ('InChIKey', 'NPRHVSBSZMAEIN-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '20.23'), ('Refractivity', '111.22'), ('Polarizability', '39.17'), ('Rotatable Bond Count', '8'), ('H Bond Acceptor Count', '1'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '13.69'), ('pKa (strongest basic)', '-3.4'), ('Physiological Charge', '1'), ('Number of Rings', '2'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"440\", \"pubChemCompound\": \"369\", \"pubChemSubstance\": \"457\", \"Clinical_status\": 1}}, {\"model\": \"drug.drug\", \"pk\": \"DB00572\", \"fields\": {\"drugtype\": 1, \"name\": \"Atropine\", \"groups\": \"4\", \"categories\": \"510\", \"description\": \"An alkaloid, originally from Atropa belladonna, but found in other plants, mainly solanaceae.\", \"aliases\": \"Atropine Care|Atropine Injection Bp 0.4mg/ml|Atropine Sulfate Inj 0.6mg/ml|Atropine Injection Bp 0.6mg/ml|Minims Atropine Sulphate|Atropine Injection BP|N/a|Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate and Scopolamine Hydrobromide|Atropisol|Atropine 1%|Atropine Ont 1%|R.O.-atropine|Atropine Sulfate Inj 0.4mg/ml|Phenobarbital with Belladonna Alkaloids - Grape|Lomotil|ATROPEN Auto-Injector|Phenobarbital with Belladonna Alkaloids - Mint|Enlon-Plus|Donnatal Tab|PB Hyos|Se-donna Pb Hyos|Donnagel Liq|Odan-atropine|Atropine Sulfate Inj 0.1mg/ml|Re-PB Hyos|Atropisol Oph Soln 1%|Urised|Atropine Sulfate|Atropine Sulfate Inj 0.3mg/ml|Phenohytro|Diphenoxylate Hcl and Atropine Sulfate|DuoDote|Donnatal Elixir|Belladonna Alkaloids with Phenobartbital|Donnatal|Phenobarbital With Belladonna Alkaloids|ATNAA atropine and pralidoxime chloride Auto-Injector|Atropine Sulfate Inj 0.4mg/0.5ml|Me-PB-Hyos|Motofen|Belladonna Alkaloids with Phenobarbital|Enlon Plus|Servira|\\n      |Diban Cap|Isopto Atropine|Vitetal|Re-PB Hyos Elixir|B-Donna|Phenobarbital with Belladonna Alkaloids|Diphenoxylate hydrochloride and atropine sulfate|Atropine|Atropine Sulfate Injection|Diphenoxylate Hydrochloride and Atropine Sulfate|Atropine Sulphate 1% - Liq Oph|Donnatal Extentabs|Atropine Sulfate Inj 1mg/ml|Atropine Sulfate Injection USP|Quadrapax|Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide|Donnatal Extentabs Srt\", \"superclass\": \"12\", \"classname\": \"63\", \"subclass\": \"1\", \"direct_parent\": \"147\", \"indication\": \"For the treatment of poisoning by susceptible organophosphorous nerve agents having anti-cholinesterase activity (cholinesterase inhibitors) as well as organophosphorous or carbamate insecticides.\", \"pharmacodynamics\": \"Atropine, a naturally occurring belladonna alkaloid, is a racemic mixture of equal parts of d- and l-hyoscyamine, whose activity is due almost entirely to the levo isomer of the drug. Atropine is commonly classified as an anticholinergic or antiparasympathetic (parasympatholytic) drug. More precisely, however, it is termed an antimuscarinic agent since it antagonizes the muscarine-like actions of acetylcholine and other choline esters. Adequate doses of atropine abolish various types of reflex vagal cardiac slowing or asystole. The drug also prevents or abolishes bradycardia or asystole produced by injection of choline esters, anticholinesterase agents or other parasympathomimetic drugs, and cardiac arrest produced by stimulation of the vagus. Atropine may also lessen the degree of partial heart block when vagal activity is an etiologic factor. Atropine in clinical doses counteracts the peripheral dilatation and abrupt decrease in blood pressure produced by choline esters. However, when given by itself, atropine does not exert a striking or uniform effect on blood vessels or blood pressure.\", \"moa\": \"Atropine binds to and inhibit muscarinic acetylcholine receptors, producing a wide range of anticholinergic effects.\", \"absorption\": \"Atropine is rapidly and well absorbed after intramuscular administration. Atropine disappears rapidly from the blood and is distributed throughout the various body tissues and fluids.\", \"toxicity\": \"Oral, mouse: LD<sub>50</sub> = 75 mg/kg. Symptoms of overdose includes widespread paralysis of parasympathetically innervated organs. Dry mucous membranes, widely dilated and nonresponsive pupils, tachycardia, fever and cutaneous flush are especially prominent, as are mental and neurological symptoms. In instances of severe intoxication, respiratory depression, coma, circulatory collapse and death may occur.\", \"halflife\": \"3.0 &plusmn; 0.9 hours in adults. The half-life of atropine is slightly shorter (approximately 20 minutes) in females than males.\", \"distribution_volume\": \"None\", \"protein_binding\": \"The protein binding of atropine is 14 to 22% in plasma.\", \"dosages\": \"[('', 'Intramuscular; Intravenous; Subcutaneous'), ('', 'Intramuscular'), ('0.25 mg/0.3mL', 'Intramuscular'), ('', 'Parenteral'), ('', 'Intramuscular; Intravenous; Subcutaneous'), ('10 mg', 'Conjunctival; Ophthalmic'), ('0.5 %', 'Intravenous'), ('1 %', 'Intravenous'), ('0.5 g/100ml', 'Ophthalmic'), ('0.5 %', 'Ophthalmic'), ('1 g/100ml', 'Ophthalmic'), ('10 MG/ML', 'Ophthalmic'), ('5 MG/ML', 'Ophthalmic'), ('', 'Ophthalmic'), ('0.1 MG/ML', ''), ('0.21 MG/ML', 'Parenteral'), ('0.5 MG/ML', 'Parenteral'), ('1 MG/ML', 'Parenteral'), ('1 mg', 'Intravenous; Subcutaneous'), ('1 mg', 'Intravenous'), ('1 mg', 'Intramuscular; Intravenous; Subcutaneous'), ('1 mg', 'Intramuscular; Subcutaneous'), ('', ''), ('1 %', 'Ophthalmic'), ('10 mg/1mL', 'Ophthalmic'), ('0.4 mg / mL', 'Intramuscular; Intravenous; Subcutaneous'), ('600 mcg/ml', 'Intramuscular; Intravenous; Subcutaneous'), ('1 %', 'Ophthalmic'), ('', ''), ('0.4 mg/1mL', 'Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous'), ('0.4 mg/1mL', 'Intramuscular; Intravenous; Subcutaneous'), ('0.05 mg/1mL', 'Intravenous'), ('0.1 mg/1mL', 'Intravenous'), ('0.1 mg/1mL', 'Intravenous; Parenteral'), ('0.1 mg/1mL', 'Parenteral'), ('0.4 mg/1mL', 'Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous'), ('0.05 mg/1mL', 'Endotracheal; Intramuscular; Intravenous; Subcutaneous'), ('0.1 mg/1mL', 'Endotracheal; Intramuscular; Intravenous; Subcutaneous'), ('0.1 mg/1mL', 'Intramuscular'), ('0.1 mg/1mL', 'Intramuscular; Intravenous; Subcutaneous'), ('0.4 mg/0.5mL', 'Intramuscular; Intravenous; Subcutaneous'), ('0.4 mg/1mL', 'Intramuscular; Intravenous; Subcutaneous'), ('1 mg/1mL', 'Intramuscular; Intravenous; Subcutaneous'), ('0.05 mg/1mL', 'Intravenous'), ('0.1 mg/1mL', 'Intravenous'), ('0.4 mg/1mL', 'Intravenous'), ('1 mg/1mL', 'Intravenous'), ('10 mg/1g', 'Ophthalmic'), ('1 mg/1mL', 'Ophthalmic'), ('.1 mg / mL', 'Intravenous'), ('0.3 mg / mL', 'Intramuscular; Intravenous; Subcutaneous'), ('0.8 mg / mL', 'Intramuscular; Intravenous; Subcutaneous'), ('0.6 mg / mL', 'Intramuscular; Intravenous; Subcutaneous'), ('1 mg / mL', 'Intramuscular; Intravenous; Subcutaneous'), ('0.5 mg / 5 mL', 'Intramuscular; Intravenous; Subcutaneous'), ('1 mg / 5 mL', 'Intramuscular; Intravenous; Subcutaneous'), ('3 mg / 10 mL', 'Intramuscular; Intravenous; Subcutaneous'), ('.6 mg / mL', 'Intramuscular; Intravenous; Subcutaneous'), ('1 mg / 10 mL', 'Intramuscular; Intravenous; Subcutaneous'), ('0.6 mg/1ml', ''), ('0.6 mg/ml', 'Intramuscular; Intravenous; Subcutaneous'), ('', 'Parenteral'), ('1 mg/ml', 'Parenteral'), ('', ''), ('1 mg', 'Parenteral'), ('10 mg / mL', 'Ophthalmic'), ('10.0 mg/ml', 'Ophthalmic'), ('0.025 mg', 'Oral'), ('', 'Ophthalmic'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('', 'Intravenous'), ('', 'Intravenous'), ('10 mg/1mL', 'Ophthalmic'), ('1 %', 'Ophthalmic'), ('2.5 mg', 'Oral'), ('', 'Ophthalmic'), ('', 'Oral'), ('', 'Oral'), ('0.025 mg', 'Oral'), ('600 mcg/ml', 'Intramuscular; Intravenous; Subcutaneous'), ('1 % w/v', 'Ophthalmic'), ('1 % w/v', 'Ophthalmic'), ('0.025 % W/V', 'Ophthalmic'), ('0.5 mg/0.7mL', 'Intramuscular'), ('1 mg/0.7mL', 'Intramuscular'), ('2 mg/0.7mL', 'Intramuscular'), ('', 'Ophthalmic'), ('1 mg/ml', 'Intramuscular; Intravenous; Subcutaneous'), ('', 'Oral'), ('1 %', 'Ophthalmic'), ('0.025 mg/5ml', 'Oral'), ('', 'Intramuscular; Intravenous; Subcutaneous'), ('', ''), ('0.5 mg/1ml', ''), ('1 mg/1ml', ''), ('0.6 mg', ''), ('', ''), ('', '')]\", \"properties\": \"[('logP', '2.19'), ('logS', '-2.1'), ('Water Solubility', '2.52e+00 g/l'), ('logP', '1.57'), ('IUPAC Name', '(1R,3R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 3-hydroxy-2-phenylpropanoate'), ('Traditional IUPAC Name', 'atropine'), ('Molecular Weight', '289.3694'), ('Monoisotopic Weight', '289.167793607'), ('SMILES', 'CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C1=CC=CC=C1'), ('Molecular Formula', 'C17H23NO3'), ('InChI', 'InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16?'), ('InChIKey', 'RKUNBYITZUJHSG-SPUOUPEWSA-N'), ('Polar Surface Area (PSA)', '49.77'), ('Refractivity', '80.82'), ('Polarizability', '31.28'), ('Rotatable Bond Count', '5'), ('H Bond Acceptor Count', '3'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '15.15'), ('pKa (strongest basic)', '9.39'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"497\", \"pubChemCompound\": \"427\", \"pubChemSubstance\": \"515\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB00604\", \"fields\": {\"drugtype\": 1, \"name\": \"Cisapride\", \"groups\": \"3\", \"categories\": \"540\", \"description\": \"In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.\", \"aliases\": \"Prepulsid Sus 1mg/ml|Cisapride|Prepulsid Tab 20mg|Prepulsid Tab 5mg|Propulsid|\\n      |Prepulsid Tab 10mg\", \"superclass\": \"9\", \"classname\": \"26\", \"subclass\": \"50\", \"direct_parent\": \"257\", \"indication\": \"For the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease.\", \"pharmacodynamics\": \"Cisapride is a parasympathomimetic which acts as a serotonin 5-HT<sub>4</sub> agonist; upon activation of the receptor signaling pathway, cisapride promotes the release of acetylcholine neurotransmitters in the enteric nervous system. Cisapride stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Cisapride increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. It increases the resting tone of the lower esophageal sphincter. It has little, if any, effect on the motility of the colon or gallbladder. Cisapride does not induce muscarinic or nicotinic receptor stimulation, nor does it inhibit acetylcholinesterase activity.\", \"moa\": \"Cisapride acts through the stimulation of the serotonin 5-HT<sub>4</sub> receptors which increases acetylcholine release in the enteric nervous system (specifically the myenteric plexus). This results in increased tone and amplitude of gastric (especially antral) contractions, relaxation of the pyloric sphincter and the duodenal bulb, and increased peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit.\", \"absorption\": \"Cisapride is rapidly absorbed after oral administration, with an absolute bioavailability of 35-40%.\", \"toxicity\": \"None\", \"halflife\": \"6-12 hours\", \"distribution_volume\": \"None\", \"protein_binding\": \"97.5%\", \"dosages\": \"[('', 'Oral'), ('', ''), ('', 'Oral'), ('', ''), ('10 mg', 'Oral'), ('', 'Oral'), ('0.1 g', 'Oral'), ('5 MG', 'Oral'), ('', 'Oral'), ('1 mg / mL', 'Oral'), ('10 mg / tab', 'Oral'), ('20 mg / tab', 'Oral'), ('5 mg / tab', 'Oral'), ('1 mg/1mL', 'Oral'), ('10 mg/1', 'Oral'), ('20 mg/1', 'Oral'), ('100 mg', 'Oral'), ('10 mg', 'Oral')]\", \"properties\": \"[('logP', '2.95'), ('logS', '-4.6'), ('Water Solubility', '1.20e-02 g/l'), ('logP', '2.49'), ('IUPAC Name', '4-amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide'), ('Traditional IUPAC Name', '(+-)-cisapride'), ('Molecular Weight', '465.945'), ('Monoisotopic Weight', '465.183062343'), ('SMILES', 'CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC'), ('Molecular Formula', 'C23H29ClFN3O4'), ('InChI', 'InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1'), ('InChIKey', 'DCSUBABJRXZOMT-IRLDBZIGSA-N'), ('Polar Surface Area (PSA)', '86.05'), ('Refractivity', '122.93'), ('Polarizability', '49.11'), ('Rotatable Bond Count', '9'), ('H Bond Acceptor Count', '6'), ('H Bond Donor Count', '2'), ('pKa (strongest acidic)', '14.58'), ('pKa (strongest basic)', '8.24'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '1')]\", \"chEMBL\": \"527\", \"pubChemCompound\": \"457\", \"pubChemSubstance\": \"545\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB00725\", \"fields\": {\"drugtype\": 1, \"name\": \"Homatropine methylbromide\", \"groups\": \"0\", \"categories\": \"647\", \"description\": \"Homatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics. Homatropine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness.\", \"aliases\": \"Hycodan|Hydrocodone Bitartrate and Homatropine Methylbromide|Homatropine methylbromide|Antitussive hydrocodone bitartrate and homatropine methylbromide|Acidobyl|Tussigon|Debiline H|Hydromet\", \"superclass\": \"12\", \"classname\": \"63\", \"subclass\": \"1\", \"direct_parent\": \"147\", \"indication\": \"Used in conjunction with antacids or histamine H2-receptor antagonists in the treatment of peptic ulcers, gastric ulcers and duodenal ulcers, to reduce further gastric acid secretion and delay gastric emptying.\", \"pharmacodynamics\": \"Homatropine methylbromide belongs to the group of medicines called anti-muscarinics. Homatropine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness.\", \"moa\": \"Homatropine is a quaternary ammonium muscarinic acetylcholine receptor antagonist. The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Homatropine methylbromide inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These postganglionic receptor sites are present in the autonomic effector cells of the smooth muscle, cardiac muscle, sinoatrial and atrioventricular nodes, and exocrine glands. Depending on the dose, anticholinergics may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder.\", \"absorption\": \"None\", \"toxicity\": \"None\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('', 'Oral'), ('', 'Parenteral'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral')]\", \"properties\": \"[('logP', '-1.9'), ('logS', '-4.8'), ('Water Solubility', '5.20e-03 g/l'), ('logP', '-2.6'), ('IUPAC Name', '3-[(2-hydroxy-2-phenylacetyl)oxy]-8,8-dimethyl-8-azabicyclo[3.2.1]octan-8-ium bromide'), ('Traditional IUPAC Name', '3-[(2-hydroxy-2-phenylacetyl)oxy]-8,8-dimethyl-8-azabicyclo[3.2.1]octan-8-ium bromide'), ('Molecular Weight', '370.281'), ('Monoisotopic Weight', '369.093956286'), ('SMILES', '[Br-].C[N+]1(C)C2CCC1CC(C2)OC(=O)C(O)C1=CC=CC=C1'), ('Molecular Formula', 'C17H24BrNO3'), ('InChI', 'InChI=1S/C17H24NO3.BrH/c1-18(2)13-8-9-14(18)11-15(10-13)21-17(20)16(19)12-6-4-3-5-7-12;/h3-7,13-16,19H,8-11H2,1-2H3;1H/q+1;/p-1'), ('InChIKey', 'FUFVKLQESJNNAN-UHFFFAOYSA-M'), ('Polar Surface Area (PSA)', '46.53'), ('Refractivity', '91.72'), ('Polarizability', '31.18'), ('Rotatable Bond Count', '4'), ('H Bond Acceptor Count', '2'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '11.99'), ('pKa (strongest basic)', '-4.1'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '0'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"633\", \"pubChemCompound\": \"562\", \"pubChemSubstance\": \"652\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB00771\", \"fields\": {\"drugtype\": 1, \"name\": \"Clidinium\", \"groups\": \"0\", \"categories\": \"689\", \"description\": \"Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.\", \"aliases\": \"Chlordiazepoxide Hydrochloride/Clidinium Bromide|Clidinium|Not applicable|CHLORDIAZEPOXIDE HYDROCHLORIDE and CLIDINIUM BROMIDE|Chlordiazepoxide Clidinium|Chlordiazepoxide Hydrochloride and Clidinium Bromide|Chlordiazepoxide Hydrochloride And Clidinium Bromide|Librax|Chlorax|Pro Chlorax|Nu-chlorax Capsules USP|\\n      |Corium Cap\", \"superclass\": \"9\", \"classname\": \"26\", \"subclass\": \"38\", \"direct_parent\": \"74\", \"indication\": \"For the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.\", \"pharmacodynamics\": \"Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.\", \"moa\": \"Inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites primarily by inhibiting the M1 muscarinic receptors.\", \"absorption\": \"None\", \"toxicity\": \"Signs of toxicity include confusion, paralytic ileus, urinary hesitancy/retention, and blurred vision.\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('5 mg', 'Oral'), ('5 mg', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral')]\", \"properties\": \"[('logP', '-0.5'), ('logS', '-6'), ('Water Solubility', '3.77e-04 g/l'), ('logP', '-1.1'), ('IUPAC Name', '(1s,4s)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1-methyl-1-azabicyclo[2.2.2]octan-1-ium'), ('Traditional IUPAC Name', 'clidinium'), ('Molecular Weight', '352.4467'), ('Monoisotopic Weight', '352.191268703'), ('SMILES', 'C[N@@+]12CC[C@@H](CC1)C(C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1'), ('Molecular Formula', 'C22H26NO3'), ('InChI', 'InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1/t17-,20?,23+'), ('InChIKey', 'HOOSGZJRQIVJSZ-NNBUQUNQSA-N'), ('Polar Surface Area (PSA)', '46.53'), ('Refractivity', '112.14'), ('Polarizability', '38.76'), ('Rotatable Bond Count', '5'), ('H Bond Acceptor Count', '2'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '11.05'), ('pKa (strongest basic)', '-4.5'), ('Physiological Charge', '1'), ('Number of Rings', '4'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '0'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"8\", \"pubChemCompound\": \"604\", \"pubChemSubstance\": \"694\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB00782\", \"fields\": {\"drugtype\": 1, \"name\": \"Propantheline\", \"groups\": \"0\", \"categories\": \"699\", \"description\": \"A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.\", \"aliases\": \"Pro-banthine Tablets 7.5 mg|Pro-banthine Tablets 15mg|Pro-Banthine|Propantheline Bromide|\\n      |Propanthel Tab 15mg|Propantheline\", \"superclass\": \"4\", \"classname\": \"34\", \"subclass\": \"35\", \"direct_parent\": \"277\", \"indication\": \"For the treatment of enuresis. It has also been used for hyperhidrosis, and cramps or spasms of the stomach, intestines or bladder.\", \"pharmacodynamics\": \"Propantheline is an anticholinergic drug, a medication that reduces the effect of acetylcholine, a chemical released from nerves that stimulates muscles, by blocking the receptors for acetylcholine on smooth muscle (a type of muscle). It also has a direct relaxing effect on smooth muscle. Propantheline is used to treat or prevent spasm in the muscles of the gastrointestinal tract in the irritable bowel syndrome. In addition, Propantheline inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions.\", \"moa\": \"Action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic).\", \"absorption\": \"None\", \"toxicity\": \"None\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('', 'Oral'), ('15 mg/1', 'Oral'), ('7.5 mg/1', 'Oral'), ('15 mg', 'Oral'), ('7.5 mg', 'Oral'), ('15 mg/1', 'Oral')]\", \"properties\": \"[('logP', '2.66'), ('logS', '-6.8'), ('Water Solubility', '7.22e-05 g/l'), ('logP', '0.36'), ('IUPAC Name', 'methylbis(propan-2-yl)[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium'), ('Traditional IUPAC Name', 'propantheline'), ('Molecular Weight', '368.4892'), ('Monoisotopic Weight', '368.222568831'), ('SMILES', 'CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12)C(C)C'), ('Molecular Formula', 'C23H30NO3'), ('InChI', 'InChI=1S/C23H30NO3/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22/h6-13,16-17,22H,14-15H2,1-5H3/q+1'), ('InChIKey', 'VVWYOYDLCMFIEM-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '35.53'), ('Refractivity', '119.25'), ('Polarizability', '40.87'), ('Rotatable Bond Count', '7'), ('H Bond Acceptor Count', '1'), ('H Bond Donor Count', '0'), ('pKa (strongest acidic)', '18.1'), ('pKa (strongest basic)', '-7.2'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '1')]\", \"chEMBL\": \"684\", \"pubChemCompound\": \"614\", \"pubChemSubstance\": \"704\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB00804\", \"fields\": {\"drugtype\": 1, \"name\": \"Dicyclomine\", \"groups\": \"0\", \"categories\": \"716\", \"description\": \"Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.[L7982]\\r\\n\\r\\nDicyclomine was granted FDA approval on 11 May 1950.[L7967]\", \"aliases\": \"Bentyl|Dicyclomine Hydrochloride Injection USP|Formulex Cap 10mg|Dicyclomine|Spasmo Nil Tab|Dicyclomine Cap 10mg|Dicyclomine HCl|Diclophen|Dicyclomine Hydrochloride|Dicyclomine hydrochloride|Bentylol|Bentylol Tablet 20mg|Riva-dicyclomine|Dicyclomine Hydrochloride USP|Bentylol Tablet 10mg|Bentylol Dospan 30mg|Viscerol Cap 10mg|\\n      |Bentylol Inj 10mg/ml|Protylol Tab 20mg|Jamp-dicyclomine HCl|Protylol\", \"superclass\": \"3\", \"classname\": \"3\", \"subclass\": \"126\", \"direct_parent\": \"302\", \"indication\": \"Dicyclomine is indicated for the treatment of functional bowel disorder and irritable bowel syndrome.[L7967]\", \"pharmacodynamics\": \"Dicyclomine is an anticholinergic drug used to relax the smooth muscles of the intestines.[L7967] It's duration of action is not especially long as it is usually taken 4 times daily with individual doses of 20-40mg orally or 10-20mg by intramuscular injection.[L7967] Dicyclomine should not be administered intravenously.[L7967]\", \"moa\": \"Dicyclomine achieves its action partially through direct antimuscarinic activity of the M1, M3, and M2 receptors; and partially through antagonism of bradykinin and histamine.[A6556,A182555,A234659,L7967] Dicyclomine non-competitively inhibits the action of bradykinin and histamine, resulting in direct action on the smooth muscle, and decreased strength of contractions seen in spasms of the ileum.[A182555]\", \"absorption\": \"The bioavailability of dicyclomine has not been determined,[A182534] though it is likely well absorbed as the primary route of elimination is in the urine.[A182525,L7967] Dicyclomine has a T<sub>max</sub> of 1-1.5h.[L7967]\", \"toxicity\": \"Patients experiencing an overdose may present with headache, nausea, vomiting, blurred vision, dilated pupils, dizziness, dry mouth, difficulty swallowing, CNS stimulation, as well as hot, dry skin.[L7967] Treat patients with gastric lavage, emetics, activated charcoal, sedatives for excitement, and a cholinergic agent if indicated.[L7967]\\r\\n\\r\\nThe oral LD<sub>50</sub> in mice is 625mg/kg.[L7967]\", \"halflife\": \"The mean plasma elimination half life is approximately 1.8 hours.[A182525,L7967]\", \"distribution_volume\": \"The volume of distribution for a 20mg oral dose is 3.65L/kg.[L7967]\", \"protein_binding\": \"Data regarding plasma protein binding of dicyclomine is not readily available.[L7967]\", \"dosages\": \"[('5 mg/5ml', 'Oral'), ('10 mg/5mL', 'Oral'), ('20.6 mg/1', 'Oral'), ('10 mg / 5 mL', 'Oral'), ('30 mg / tab', 'Oral'), ('10 mg / mL', 'Intramuscular'), ('20 mg', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('20 mg/2mL', 'Intramuscular'), ('20 mg/1', 'Oral'), ('10 mg/1', 'Oral'), ('10 mg/1mL', 'Intramuscular'), ('10 mg/1mL', 'Intramuscular'), ('20 mg/2mL', 'Intramuscular'), ('10 mg/5mL', 'Oral'), ('10 mg/1mL', 'Oral'), ('10 mg/1', 'Oral'), ('10 mg / mL', 'Intramuscular'), ('10 mg', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('10 mg / cap', 'Oral'), ('', ''), ('', ''), ('10 mg', 'Oral'), ('10 mg', 'Oral'), ('', ''), ('', ''), ('10 mg', '')]\", \"properties\": \"[('logP', '5.82'), ('logS', '-5'), ('Water Solubility', '3.27e-03 g/l'), ('logP', '4.93'), ('IUPAC Name', '2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate'), ('Traditional IUPAC Name', 'bentyl'), ('Molecular Weight', '309.4867'), ('Monoisotopic Weight', '309.266779369'), ('SMILES', 'CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1'), ('Molecular Formula', 'C19H35NO2'), ('InChI', 'InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3'), ('InChIKey', 'CURUTKGFNZGFSE-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '29.54'), ('Refractivity', '91.78'), ('Polarizability', '37.39'), ('Rotatable Bond Count', '8'), ('H Bond Acceptor Count', '2'), ('H Bond Donor Count', '0'), ('pKa (strongest basic)', '8.96'), ('Physiological Charge', '1'), ('Number of Rings', '2'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"701\", \"pubChemCompound\": \"631\", \"pubChemSubstance\": \"721\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB00940\", \"fields\": {\"drugtype\": 1, \"name\": \"Methantheline\", \"groups\": \"1\", \"categories\": \"843\", \"description\": \"Methantheline is a synthetic antispasmodic. Antispasmodics are used to relieve cramps or spasms of the stomach, intestines, and bladder. Methantheline is used to treat intestine or stomach ulcers (peptic ulcer disease), intestine problems (irritable bowel syndrome), pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, or urinary problems (reflex neurogenic bladder in children).\", \"aliases\": \"\\n      |Methantheline\", \"superclass\": \"4\", \"classname\": \"34\", \"subclass\": \"35\", \"direct_parent\": \"277\", \"indication\": \"For the treatment of peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder in children.\", \"pharmacodynamics\": \"Methantheline is a synthetic quarternary ammonium antimuscarinic used to relieve cramps or spasms of the stomach, intestines, and bladder. It can be used together with antacids or other medicines, such as H2-receptor antagonists, in the treatment of peptic ulcer. Methantheline inhibits muscarinic actions at postganglionic parasympathetic neuroeffector sites.\", \"moa\": \"Methantheline inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These postganglionic receptor sites are present in the autonomic effector cells of the smooth muscle, cardiac muscle, sinoatrial and atrioventricular nodes, and exocrine glands. Depending on the dose, anticholinergics may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder.\", \"absorption\": \"Rapidly absorbed.\", \"toxicity\": \"Symptoms of overdose: blurred vision (continuing) or changes in near vision, clumsiness or unsteadiness, confusion, convulsions, difficulty in breathing, muscle weakness (severe), or tiredness (severe), dizziness, drowsiness (severe), dryness of mouth, nose, or throat (severe), fast heartbeat, fever, hallucinations, slurred speech, unusual excitement, nervousness, restlessness, or irritability, unusual warmth, dryness, and flushing of skin.\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[]\", \"properties\": \"[('logP', '0.5'), ('logS', '-6.4'), ('Water Solubility', '1.32e-04 g/l'), ('logP', '-0.47'), ('IUPAC Name', 'diethyl(methyl)[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium'), ('Traditional IUPAC Name', 'methantheline'), ('Molecular Weight', '340.436'), ('Monoisotopic Weight', '340.191268703'), ('SMILES', 'CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12'), ('Molecular Formula', 'C21H26NO3'), ('InChI', 'InChI=1S/C21H26NO3/c1-4-22(3,5-2)14-15-24-21(23)20-16-10-6-8-12-18(16)25-19-13-9-7-11-17(19)20/h6-13,20H,4-5,14-15H2,1-3H3/q+1'), ('InChIKey', 'GZHFODJQISUKAY-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '35.53'), ('Refractivity', '110.42'), ('Polarizability', '37.44'), ('Rotatable Bond Count', '7'), ('H Bond Acceptor Count', '1'), ('H Bond Donor Count', '0'), ('pKa (strongest acidic)', '18.1'), ('pKa (strongest basic)', '-7.2'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '0'), ('MDDR-Like Rule', '1')]\", \"chEMBL\": \"827\", \"pubChemCompound\": \"757\", \"pubChemSubstance\": \"848\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB00969\", \"fields\": {\"drugtype\": 1, \"name\": \"Alosetron\", \"groups\": \"2\", \"categories\": \"868\", \"description\": \"Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured bowel, and death. In June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use.\", \"aliases\": \"Alosetron|Alosetron Hydrochloride|Lotronex\", \"superclass\": \"4\", \"classname\": \"18\", \"subclass\": \"179\", \"direct_parent\": \"356\", \"indication\": \"Only for the treatment of symptoms of severe diarrhea-predominant irritable bowel syndrome (IBS) in women with chronic symptoms (generally lasting greater than 6 months) who does not present with anatomic or biochemical GI abnormalities and have not responded to conventional therapy.\", \"pharmacodynamics\": \"Alosetron is a potent and selective antagonist of the serotonin 5-HT<sub>3</sub> receptor type. Activation of these receptors and the resulting neuronal depolarization affects the regulation of visceral pain, colonic transit, and GI secretions processes that are related to IBS. By blocking these receptors, alosetron is able to effectively control IBS.\", \"moa\": \"Alosetron is a potent and selective 5-HT<sub>3</sub> receptor antagonist. 5-HT<sub>3</sub> receptors are nonselective cation channels that are extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels and the resulting neuronal depolarization affect the regulation of visceral pain, colonic transit and gastrointestinal secretions, processes that relate to the pathophysiology of irritable bowel syndrome (IBS). 5-HT<sub>3</sub> receptor antagonists such as alosetron inhibit activation of non-selective cation channels which results in the modulation of serotonin-sensitive GI motor and sensory processes.\", \"absorption\": \"50-60 %\", \"toxicity\": \"None\", \"halflife\": \"1.5 hours\", \"distribution_volume\": \"* 65 to 95 L\", \"protein_binding\": \"82%\", \"dosages\": \"[('0.5 mg/1', 'Oral'), ('1 mg/1', 'Oral'), ('0.5 mg/1', 'Oral'), ('1 mg/1', 'Oral'), ('1.0 mg/1', 'Oral')]\", \"properties\": \"[('logP', '1.85'), ('logS', '-2.8'), ('Water Solubility', '4.38e-01 g/l'), ('logP', '1.21'), ('IUPAC Name', '5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H,2H,3H,4H,5H-pyrido[4,3-b]indol-1-one'), ('Traditional IUPAC Name', 'alosetron'), ('Molecular Weight', '294.351'), ('Monoisotopic Weight', '294.148061218'), ('SMILES', 'CN1C2=C(C3=CC=CC=C13)C(=O)N(CC1=C(C)NC=N1)CC2'), ('Molecular Formula', 'C17H18N4O'), ('InChI', 'InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)'), ('InChIKey', 'JSWZEAMFRNKZNL-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '53.92'), ('Refractivity', '86.41'), ('Polarizability', '32.52'), ('Rotatable Bond Count', '2'), ('H Bond Acceptor Count', '2'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '13.32'), ('pKa (strongest basic)', '6.81'), ('Physiological Charge', '0'), ('Number of Rings', '4'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"853\", \"pubChemCompound\": \"783\", \"pubChemSubstance\": \"874\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB00986\", \"fields\": {\"drugtype\": 1, \"name\": \"Glycopyrronium\", \"groups\": \"6\", \"categories\": \"884\", \"description\": \"Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers.[L33110] They are both quaternary ammonium compounds and long acting muscarinic antagonists.[L33110] It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers.[A233570,L33090] Later research, taking advantage of the systemic distribution of muscarinic receptors through the body, found that glycopyrronium could also be used for reducing sweat gland,[L4755] oral,[L33140] airway, and gastric secretions;[L33120] as well as reducing cardiac inhibitory reflexes;[L33120] and reducing bronchoconstriction in COPD.[L33105] Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium].[A233565]\\r\\n\\r\\nGlycopyrronium was originally granted FDA approval on 11 August 1961.[L33090]\", \"aliases\": \"Ultibro Breezhaler|Glyrx-PF|Utibron Neohaler|Riarify|Trimbow|Trydonis|Trixeo Aerosphere|Qbrexza|Breztri|Enerzair Breezhaler|Zimbus Breezhaler|Robinul-forte Tab 2mg|Glycopyrrolate|Robinul Forte|Lonhala|Robinul|Seebri Neohaler|Glycopyrrolate Injection|Robinul Forte Tab 2mg|Tovanor Breezhaler|Bevespi Aerosphere|Xoterna Breezhaler|Glycate|Robinul Tab 1mg|Ulunar Breezhaler|Sialanar|\\n      |Glycopyrrolate Injection Multidose|Glycopyrrolate Injection USP|Enurev Breezhaler|Glycopyrronium (as Bromide) / Formoterol Fumarate Dihydrate Pressurized Inhalation Aerosol|Lonhala Magnair|Seebri Breezhaler|Glycopyrronium|Cuvposa|Robinul 0.2mg/ml Liq Inj|Breztri Aerosphere\", \"superclass\": \"2\", \"classname\": \"2\", \"subclass\": \"1\", \"direct_parent\": \"2\", \"indication\": \"Glycopyrronium formulated as a topical cloth is indicated to treat primary axillary hyperhidrosis in patients \u00e2\u0089\u00a59 years,[L4755] and an inhalational solution is indicated for long term maintenance of airflow obstruction in COPD.[L33105] A glycopyrronium intravenous and intramuscular injection is indicated in adults and pediatric patients to reduce the volume and acidity of gastric secretions, reduce airway secretions, and block cardiac inhibitory reflexes during the induction of anesthesia and intubation; to treat surgically-induced, drug-induced, or vagal reflex associated arrhythmias intraoperatively; and to prevent peripheral muscarinic effects of cholinergic drugs.[L33120] The same injection is indicated in adults as an adjunct therapy in the treatment of peptic ulcers.[L33120] An oral solution is indicated to treat excessive drooling associated with neurologic conditions in patients aged 3-16 years.[L33140] Glycopyrronium and [budesonide][L33145] can be formulated with [formoterol] fumarate for the maintenance of COPD.[L33150]\", \"pharmacodynamics\": \"Glycopyrronium is a quaternary ammonium compound that is one of the most commonly prescribed long acting muscarinic antagonists.[A233535,A233540,L33110] Glycopyrronium slowly dissociated from muscarinic receptors, leading to a long duration of action.[A18287] It has a wider therapeutic index than other anticholinergic medications, such as [tiotropium].[A233565] Patients should be counselled regarding the risk of worsening urinary retention, risk of overheating, and transient blurred vision.[L4755]\", \"moa\": \"Glycopyrronium is a muscarinic antagonist with the highest affinity for M1 receptors, followed by M3, M2/M4, and M5.[L33115] \\r\\n\\r\\nMuscarinic receptors M1 to M4 are found in the lung, although M3 is predominantly responsible for bronchoconstriction and airway secretions.[A18287,L33145,L33115] Secretions from salivary[A233545] and sweat[A233550] glands, as well as gastric acid secretions,[A233555] are also predominantly mediated by the M3 receptor. Salivary[A233545] and gastric acid[A233555] secretions are also partially mediated by the M1 receptor. Antagonism of these receptors decreases the volume of their respective secretions, and in the case of the gastrointestinal system, reduces the acidity of the stomach.[A233560]\\r\\n\\r\\nIn the cardiovascular system, muscarinic receptors M1 to M5 are all present, however the function of M5 has not been described in literature.[A233560] Under normal circumstances, stimulation of the vagal nerve lowers the heart rate, potentially leading to intraoperative bradycardia.[A233560] Studies in mice suggest that this stimulation is predominantly mediated by the M3 receptor, and mutant knockout mice are not susceptible to these effects.[A233560]\", \"absorption\": \"In adults, a 66 mg topical dose of glycopyrronium reaches a C<sub>max</sub> of 0.08 \u00c2\u00b1 0.04 ng/mL, with a T<sub>max</sub> of 1 hour, and an AUC<sub>0-24</sub> of 0.88 \u00c2\u00b1 0.57 h\\\\*ng/mL.[L4755]\\r\\n\\r\\nInhaled glycopyrronium is approximately 40% bioavailable.[L33110] A 25 \u00c2\u00b5g inhaled solution reaches a C<sub>max</sub> of 34.5 pg/mL, with a T<sub>max</sub> of <20 minutes, and an AUC<sub>0-inf</sub> of 255 h\\\\*pg/mL.[L33105]\\r\\n\\r\\nAn 8 \u00c2\u00b5g/kg intramuscular dose reaches a C<sub>max</sub> of 3.47 \u00c2\u00b1 1.48 \u00c2\u00b5g/L, with a T<sub>max</sub> of 27.48 \u00c2\u00b1 6.12 minutes, and an AUC of 6.64 \u00c2\u00b1 2.33 h\\\\*g/L.[L33120]\\r\\n\\r\\nOral glycopyrronium has highly variable pharmacokinetics, reaching a mean C<sub>max</sub> of 0.318 ng/mL, a T<sub>max</sub> of 3.1 hours, and an AUC<sub>0-24</sub> of 1.74 h\\\\*ng/mL.[L33140]\", \"toxicity\": \"Patients presenting with an overdose typically present with flushing, hyperthermia, tachycardia, ileus, urinary retention, loss of ocular accommodation, light sensitivity, mydriasis, nausea, vomiting, dizziness, light headedness, and obstipation.[L4755,L33105] Patients should be treated with symptomatic and supportive therapy, which may include the use of catheters for urinary retention, cardiovascular support, airway maintenance, ventilation, or neostigmine.[L4755]\\r\\n\\r\\nThe oral LD<sub>50</sub> in mice is 570 mg/kg, and in rats is 709 mg/kg.[L33100] The intraperitoneal LD<sub>50</sub> in mice is 90 mg/kg, and in rats is 196 mg/kg.[L33100]\", \"halflife\": \"The half life after inhalation is approximately 33-53 hours.[L33110] The mean half life of a 6 \u00c2\u00b5g/kg intravenous dose is 0.83 \u00c2\u00b1 0.27 hours.[L33120] The mean half life of oral glycopyrronium is 3.0 hours.[L33140]\", \"distribution_volume\": \"The mean volume of distribution in patients aged 1-14 years old is 1.3-1.8 L/kg, with a range of 0.7-3.9 L/kg.[L4755] The volume of distribution in adults aged 60-75 years is 0.42 \u00c2\u00b1 0.22 L/kg.[L4755]\", \"protein_binding\": \"Glycopyrronium is 38-44% protein bound in plasma.[L33110] It is bound to serum albumin, alpha-1-acid glycoprotein, as well as other plasma proteins that have not been identified in literature.[L33115]\", \"dosages\": \"[('7.2 mcg', 'Respiratory (inhalation)'), ('', 'Respiratory (inhalation)'), ('', 'Respiratory (inhalation)'), ('', 'Respiratory (inhalation)'), ('1 mg/5mL', 'Oral'), ('1 mg / 5 mL', 'Oral'), ('1 mg/5mL', 'Oral'), ('50 mcg', 'Respiratory (inhalation)'), ('200 MICROGRAMMI/ML', ''), ('200 mcg/ml', 'Intramuscular; Intravenous'), ('1.5 mg/1', 'Oral'), ('0.2 mg/1ml', ''), ('0.2 mg/1mL', 'Intramuscular; Intravenous'), ('0.4 mg/2mL', 'Intramuscular; Intravenous'), ('1 mg/5mL', 'Intramuscular; Intravenous'), ('4 mg/20mL', 'Intramuscular; Intravenous'), ('0.2 mg/1mL', 'Intramuscular; Intravenous'), ('0.4 mg/2mL', 'Intramuscular; Intravenous'), ('1 mg/5mL', 'Intramuscular; Intravenous'), ('0.2 mg/1mL', 'Intravenous'), ('0.4 mg/2mL', 'Intravenous'), ('1 mg/5mL', 'Intravenous'), ('5 mg/20mL', 'Intravenous'), ('1 g/1g', 'Not applicable'), ('1 mg/1', 'Oral'), ('2 mg/1', 'Oral'), ('0.2 mg / mL', 'Intramuscular; Intravenous'), ('0.2 mg / mL', 'Intramuscular; Intravenous'), ('0.2 mg / 1 mL', 'Intramuscular; Intravenous'), ('0.4 mg / 2 mL', 'Intramuscular; Intravenous'), ('4 mg / 20 mL', 'Intramuscular; Intravenous'), ('', 'Parenteral'), ('0.2 mg/1mL', 'Intramuscular; Intravitreal'), ('25 ug/1mL', 'Respiratory (inhalation)'), ('', 'Respiratory (inhalation)'), ('', 'Intramuscular; Intravenous'), ('2.4 g/100g', 'Topical'), ('0.2 mg/ml', 'Intramuscular; Intravenous'), ('.2 mg / mL', 'Intramuscular; Intravenous'), ('2 mg / tab', 'Oral'), ('1 mg', 'Oral'), ('2 mg', 'Oral'), ('50 cg', 'Respiratory (inhalation)'), ('', 'Respiratory (inhalation)'), ('44 MCG', 'Respiratory (inhalation)'), ('50 mcg', 'Respiratory (inhalation)'), ('50 mcg', 'Respiratory (inhalation)'), ('50 mcg', 'Buccal'), ('15.6 ug/1', 'Respiratory (inhalation)'), ('320 MICROGRAMMI/ML', 'Oral'), ('320 MCG/ML', 'Oral'), ('320 ?g/ml', 'Oral'), ('320 \u00ce\u00bcg/ml', 'Oral'), ('44 micrograms', 'Respiratory (inhalation)'), ('', 'Respiratory (inhalation)'), ('', 'Respiratory (inhalation)'), ('0.1 mg', 'Respiratory (inhalation)'), ('', 'Respiratory (inhalation)'), ('', 'Respiratory (inhalation)'), ('50 mcg', 'Buccal'), ('', 'Respiratory (inhalation)'), ('', 'Respiratory (inhalation)'), ('', 'Respiratory (inhalation)')]\", \"properties\": \"[('logP', '-1.2'), ('logS', '-5.6'), ('Water Solubility', '9.44e-04 g/l'), ('logP', '-1.4'), ('IUPAC Name', '3-[(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidin-1-ium'), ('Traditional IUPAC Name', 'glycopyrrolate'), ('Molecular Weight', '318.4305'), ('Monoisotopic Weight', '318.206918767'), ('SMILES', 'C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1'), ('Molecular Formula', 'C19H28NO3'), ('InChI', 'InChI=1S/C19H28NO3/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3/q+1'), ('InChIKey', 'ANGKOCUUWGHLCE-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '46.53'), ('Refractivity', '101.08'), ('Polarizability', '35.88'), ('Rotatable Bond Count', '5'), ('H Bond Acceptor Count', '2'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '11.53'), ('pKa (strongest basic)', '-4.3'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '0'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"869\", \"pubChemCompound\": \"799\", \"pubChemSubstance\": \"890\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB01113\", \"fields\": {\"drugtype\": 1, \"name\": \"Papaverine\", \"groups\": \"1\", \"categories\": \"1002\", \"description\": \"An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.\", \"aliases\": \"\\n      |Papaverine Hydrochloride|Papaverine Hydrochloride Injection USP|Papaverine\", \"superclass\": \"4\", \"classname\": \"71\", \"subclass\": \"128\", \"direct_parent\": \"240\", \"indication\": \"For the treatment of impotence and vasospasms.\", \"pharmacodynamics\": \"Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries.\", \"moa\": \"Perhaps by its direct vasodilating action on cerebral blood vessels, Papaverine increases cerebral blood flow and decreases cerebral vascular resistance in normal subjects; oxygen consumption is unaltered. These effects may explain the benefit reported from the drug in cerebral vascular encephalopathy.\", \"absorption\": \"None\", \"toxicity\": \"None\", \"halflife\": \"0.5-2 hours\", \"distribution_volume\": \"None\", \"protein_binding\": \"~90%\", \"dosages\": \"[('', 'Oral'), ('40 MG/ML', 'Intramuscular; Intravenous'), ('', 'Intramuscular; Intravenous'), ('', 'Intra-arterial; Intramuscular; Intravenous'), ('30 MG/2ML', ''), ('50 MG/3ML', ''), ('', ''), ('', ''), ('', ''), ('', ''), ('40 mg', 'Intramuscular; Intravenous'), ('30 mg/1mL', 'Intramuscular; Intravenous'), ('30 mg/1mL', 'Intramuscular; Intravenous'), ('30 mg/1mL', 'Intravenous'), ('30 mg/1mL', 'Parenteral'), ('65 mg / 2 mL', 'Intramuscular; Intravenous; Subcutaneous')]\", \"properties\": \"[('logP', '4.19'), ('logS', '-4.4'), ('Water Solubility', '1.29e-02 g/l'), ('logP', '3.08'), ('IUPAC Name', '1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline'), ('Traditional IUPAC Name', 'papaverine'), ('Molecular Weight', '339.385'), ('Monoisotopic Weight', '339.147058165'), ('SMILES', 'COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1'), ('Molecular Formula', 'C20H21NO4'), ('InChI', 'InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3'), ('InChIKey', 'XQYZDYMELSJDRZ-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '49.81'), ('Refractivity', '95.52'), ('Polarizability', '36.57'), ('Rotatable Bond Count', '6'), ('H Bond Acceptor Count', '5'), ('H Bond Donor Count', '0'), ('pKa (strongest basic)', '6.03'), ('Physiological Charge', '0'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '1')]\", \"chEMBL\": \"987\", \"pubChemCompound\": \"916\", \"pubChemSubstance\": \"1010\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB01184\", \"fields\": {\"drugtype\": 1, \"name\": \"Domperidone\", \"groups\": \"6\", \"categories\": \"1067\", \"description\": \"A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.\", \"aliases\": \"Motilium Tab 10mg|PMS-domperidone|Ran-domperidone|Ava-domperidone|Dom-domperidone|Domperidone|Priva-domperidone|Teva-domperidone|Motilidone|Domperidone-10|Mar-domperidone|Nu-domperidone 10 Mg Tablets|Bio-domperidone|\\n      |Jamp-domperidone|Mylan-domperidone|Prz-domperidone|Ipg-domperidone|Ftp-domperidone Maleate|Apo-domperidone - Tab 10mg\", \"superclass\": \"4\", \"classname\": \"37\", \"subclass\": \"1\", \"direct_parent\": \"268\", \"indication\": \"For management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.\", \"pharmacodynamics\": \"Domperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.\", \"moa\": \"Domperidone acts as a gastrointestinal emptying (delayed) adjunct and peristaltic stimulant. The gastroprokinetic properties of domperidone are related to its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Antiemetic: The antiemetic properties of domperidone are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level. It has strong affinities for the D2 and D3 dopamine receptors, which are found in the chemoreceptor trigger zone, located just outside the blood brain barrier, which - among others - regulates nausea and vomiting\", \"absorption\": \"None\", \"toxicity\": \"Side effects include galactorrhea, gynecomastia, or menstrual irregularities.\", \"halflife\": \"7 hours\", \"distribution_volume\": \"None\", \"protein_binding\": \"91%-93%\", \"dosages\": \"[('', 'Oral'), ('0.1 %', 'Oral'), ('', 'Oral'), ('10 MG', 'Oral'), ('', 'Oral'), ('10 MG', ''), ('60 MG', 'Rectal'), ('12725 MG', 'Oral'), ('12.73 MG', 'Oral'), ('12.73 MG', 'Oral'), ('10 mg/tablet', 'Oral'), ('5 MG/5ML', 'Oral'), ('', 'Oral'), ('0.1 g', 'Oral'), ('', ''), ('', ''), ('100 mg', 'Oral'), ('', 'Oral'), ('10 MG', ''), ('10 mg/2ml', 'Intramuscular; Intravenous'), ('4 mg/2ml', 'Intramuscular; Intravenous'), ('10 mg/ml', 'Oral'), ('20 mg/ml', 'Oral'), ('20 ML', 'Oral'), ('1 MG/ML', 'Oral'), ('20 MG', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('1 mg/ml', 'Oral'), ('', ''), ('', ''), ('', 'Oral'), ('10 MG', 'Rectal'), ('30 MG', 'Rectal'), ('', 'Oral'), ('10000 MG', 'Oral'), ('', ''), ('', ''), ('10 mg', 'Oral'), ('10 mg', 'Oral')]\", \"properties\": \"[('logP', '3.7'), ('logS', '-3.7'), ('Water Solubility', '9.25e-02 g/l'), ('logP', '2.9'), ('IUPAC Name', '5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one'), ('Traditional IUPAC Name', 'motilium'), ('Molecular Weight', '425.911'), ('Monoisotopic Weight', '425.161852744'), ('SMILES', 'ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2'), ('Molecular Formula', 'C22H24ClN5O2'), ('InChI', 'InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)'), ('InChIKey', 'FGXWKSZFVQUSTL-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '67.92'), ('Refractivity', '119.37'), ('Polarizability', '45.61'), ('Rotatable Bond Count', '5'), ('H Bond Acceptor Count', '3'), ('H Bond Donor Count', '2'), ('pKa (strongest acidic)', '12.52'), ('pKa (strongest basic)', '7.03'), ('Physiological Charge', '1'), ('Number of Rings', '5'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"1052\", \"pubChemCompound\": \"980\", \"pubChemSubstance\": \"1075\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB01233\", \"fields\": {\"drugtype\": 1, \"name\": \"Metoclopramide\", \"groups\": \"1\", \"categories\": \"1114\", \"description\": \"Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system.[A184934] Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures.[L8417] \\r\\n\\r\\nOne unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route.[T683] Metoclopramide was initially approved by the FDA in 1980.[A184922]\", \"aliases\": \"Reglan Inj 5mg/ml|PCP 100 Kit|Nu-metoclopramide-tab 5mg|Metoclopramide hydrochloride|Metoclopramide Omega|PMS-metoclopramide Hydrochloride Tablets|Reglan Syr 1mg/ml|Reglan Syrup 1mg/ml|Nu-metoclopramide-tab 10mg|Metoclopramide|Metoclopramide Hydrochloride Injection|PMS-metoclopramide Tablets|PMS-metoclopramide Hydrochloride Injection|Maxeran 5mg Tab|Maxeran-5 (5mg Tablet)|Metoclopramide Tab 10mg|METOCLOPRAMIDE hydrochloride|PMS-metoclopramide Hydrochloride Oral Solution|Gimoti|Metoclopramide Hydrochloride Injection Hs|PMS-metoclopramide Oral Solution|Maxeran Liq|Reglan-5 Tab 5mg|Maxeran-10 (10mg Tablet)|\\n      |Reglan Tab 5mg|Reglan|Apo-metoclop Tab 5mg|Reglan Tab 10mg|Reglan Injectable Liq 5mg/ml|Metoclopramide Tab 5mg|Mar-metoclopramide|Metozolv ODT|Apo-metoclop Tab 10mg|Metoclopramide Hydrochloride\", \"superclass\": \"9\", \"classname\": \"29\", \"subclass\": \"203\", \"direct_parent\": \"409\", \"indication\": \"Metoclopramide in the oral tablet form is used for symptomatic treatment of both acute and recurrent diabetic gastroparesis, in addition to the treatment of gastroesophageal reflux disease (GERD) in patients who have failed to respond to traditional therapy.[L8414] A nasal spray formulation is also indicated to treat adults with acute, recurrent diabetic gastroparesis.[L14381]\\r\\n\\r\\nIn the intravenous injection form, it is indicated for the above conditions as well as for the prevention of vomiting that may follow emetogenic chemotherapy or nausea and vomiting after surgery. Intravenous metoclopramide facilitates intubation of the small bowel and stimulates gastric emptying and barium flow in patients who require radiological examination of the stomach or small intestine.  In some cases, the delay of gastrointestinal emptying interferes with the radiographic visualization of the gastrointestinal tract, and metoclopramide is used to facilitate emptying in these cases, allowing for adequate diagnostic visualization.[L8417]\\r\\n\\r\\nSome off-label uses of metoclopramide include the management of radiation-induced nausea and vomiting, gastric bezoars, intractable hiccups, and migraine pain.[A184961,A184964,A184967,A40105]\", \"pharmacodynamics\": \"Metoclopramide increases gastric emptying by decreasing lower esophageal sphincter (LES) pressure. It also exerts effects on the area postrema of the brain, preventing and relieving the symptoms of nausea and vomiting. In addition, this drug increases gastrointestinal motility without increasing biliary, gastric, or pancreatic secretions.[T683,L8414,L8417]\\r\\n\\r\\nBecause of its antidopaminergic activity, metoclopramide can cause symptoms of tardive dyskinesia (TD), dystonia, and akathisia, and should therefore not be administered for longer than 12 weeks.[A184886,L8414]\", \"moa\": \"Metoclopramide causes antiemetic effects by inhibiting dopamine D2 and serotonin 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) located in the area postrema of the brain.[A184880,T683] Administration of this drug leads to prokinetic effects via inhibitory actions on presynaptic and postsynaptic D2 receptors, agonism of serotonin 5-HT4 receptors, and antagonism of muscarinic receptor inhibition. This action enhances the release of acetylcholine, causing increased lower esophageal sphincter (LES) and gastric tone, accelerating gastric emptying and transit through the gut. Metoclopramide antagonizes the dopamine D2 receptors. Dopamine exerts relaxant effect on the gastrointestinal tract through binding to muscular D2 receptors.[A184880,T683,L8414]\", \"absorption\": \"Metoclopramide is rapidly absorbed in the gastrointestinal tract with an absorption rate of about 84%.[A184886] The bioavailability of the oral preparation is reported to be about 40.7%, but can range from 30-100%.[A184880,A184949]\\r\\n\\r\\nNasal metoclopramide is 47% bioavailable.[L14381] A 15mg dose reaches a C<sub>max</sub> of 41.0 ng/mL, with a T<sub>max</sub> of 1.25 h, and an AUC of 367 ng\\\\*h/mL.[L14381]\", \"toxicity\": \"The rat oral LD50 of metoclopramide is 750 mg/kg.[L8465]\\r\\n\\r\\nSome symptoms of an overdose with metoclopramide include drowsiness, disorientation, and extrapyramidal reactions. Drugs that manage Parkinson's disease or anticholinergic drugs or antihistamines with anticholinergic properties [A185174] should be employed to treat extrapyramidal symptoms. Normally, these symptoms subside within 24 hours.[L8414] Unintentional overdose in infants receiving the oral solution of metoclopramide resulted in seizures, extrapyramidal symptoms, in addition to a lethargic state.\\r\\n\\r\\nIn addition, methemoglobinemia has been found to occur in premature and full-term neonates after a metoclopramide overdose. Intravenous methylene blue may treat metoclopramide-associated methemoglobinemia. It is important to note that methylene blue administration may lead to hemolytic anemia in patients who suffer from G6PD deficiency, which can result in fatality. Dialysis has not been shown to be effective in sufficiently eliminating metoclopramide in an overdose situation due to low plasma distribution of this drug.[L8414]\", \"halflife\": \"The mean elimination half-life of metoclopramide in people with healthy renal function ranges from 5 to 6 hours but is prolonged in patients with renal impairment. Downward dose adjustment should be considered.[A184886,A185153,L8414]\", \"distribution_volume\": \"The volume of distribution of metoclopramide is approximately 3.5 L/kg. This implies a high level of tissue distribution. Metoclopramide crosses the placental barrier and can cause extrapyramidal symptoms in the fetus.[A185153,L8414]\", \"protein_binding\": \"Metoclopramide is 30% bound to plasma proteins, mainly to alpha-1-acid glycoprotein.[A185000,L8417]\", \"dosages\": \"[('', 'Intramuscular; Intravenous'), ('15 mg', 'Oral'), ('', 'Oral'), ('', 'Parenteral'), ('', ''), ('', ''), ('', ''), ('', 'Oral'), ('', 'Oral'), ('', ''), ('', 'Oral'), ('', 'Oral'), ('15 mg/0.07mL', 'Nasal'), ('1 mg / 1 mL', 'Oral'), ('1 MG/ML', 'Oral'), ('10.54 mg', 'Oral'), ('30 mg', 'Oral'), ('10 MG/2ML', ''), ('5 MG/ML', 'Intramuscular; Intravenous'), ('10 mg', 'Intramuscular; Intravenous'), ('10 mg', 'Parenteral'), ('4 mg', 'Oral'), ('100 mg', 'Oral'), ('', ''), ('5 mg/1mL', 'Intramuscular; Intravenous'), ('10 mg/2mL', 'Intramuscular; Intravenous'), ('5 mg/1mL', 'Intramuscular; Intravenous'), ('0.9 mg/0.9mL', 'Oral'), ('10 mg/10mL', 'Oral'), ('5 mg/5mL', 'Oral'), ('10 mg/1', 'Oral'), ('5 mg/1', 'Oral'), ('', ''), ('5 mg/1mL', 'Intravenous'), ('1 g/1g', 'Not applicable'), ('10 mg/1', 'Oral'), ('5 mg/1', 'Oral'), ('5 mg / mL', 'Intramuscular; Intravenous'), ('5 mg / mL', 'Intravenous'), ('10 MG/2ML', 'Parenteral'), ('5 mg/ml', 'Parenteral'), ('', 'Oral'), ('', 'Intramuscular; Intravenous'), ('', 'Oral'), ('', 'Intravenous'), ('10 MG', 'Oral'), ('100 mg', 'Oral'), ('20 mg', 'Oral'), ('50 mg', 'Oral'), ('', 'Oral'), ('4 MG/ML', 'Oral'), ('10 MG/10ML', 'Oral'), ('', 'Oral'), ('5 mg / mL', 'Intramuscular; Intravenous'), ('5 mg / 5 mL', 'Oral'), ('5 mg', 'Oral'), ('', 'Nasal'), ('', ''), ('10 MG', 'Rectal'), ('100 mg', 'Intramuscular; Intravenous'), ('0.09 g', 'Oral'), ('10 mg', 'Oral'), ('10 mg/2ml', 'Intramuscular; Intravenous'), ('', 'Oral'), ('5.0 mg/1.0mL', 'Intramuscular; Intravenous'), ('1 mg / mL', 'Oral'), ('10 mg / tab', 'Oral'), ('5 mg / tab', 'Oral'), ('', 'Intramuscular; Intravenous'), ('5 mg/1ml', ''), ('5 mg/5ml', ''), ('5 mg/5mL', 'Oral')]\", \"properties\": \"[('logP', '2.18'), ('logS', '-3'), ('Water Solubility', '3.10e-01 g/l'), ('logP', '1.4'), ('IUPAC Name', '4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide'), ('Traditional IUPAC Name', 'cefazolin sodium'), ('Molecular Weight', '299.796'), ('Monoisotopic Weight', '299.14005467'), ('SMILES', 'CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC'), ('Molecular Formula', 'C14H22ClN3O2'), ('InChI', 'InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)'), ('InChIKey', 'TTWJBBZEZQICBI-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '67.59'), ('Refractivity', '83.52'), ('Polarizability', '32.7'), ('Rotatable Bond Count', '7'), ('H Bond Acceptor Count', '4'), ('H Bond Donor Count', '2'), ('pKa (strongest acidic)', '14.49'), ('pKa (strongest basic)', '9.04'), ('Physiological Charge', '1'), ('Number of Rings', '1'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"1099\", \"pubChemCompound\": \"1026\", \"pubChemSubstance\": \"1122\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB01425\", \"fields\": {\"drugtype\": 1, \"name\": \"Alizapride\", \"groups\": \"24\", \"categories\": \"1239\", \"description\": \"Alizapride is a dopamine antagonist that is capable of demonstrating both prokinetic and antiemetic effects. This kind of pharmacological activity makes it effective for use in the treatment of various kinds of nausea and vomiting, including that which may occur postoperatively.\", \"aliases\": \"\\n      |Alizapride\", \"superclass\": \"4\", \"classname\": \"144\", \"subclass\": \"1\", \"direct_parent\": \"430\", \"indication\": \"Alizapride is used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. \", \"pharmacodynamics\": \"Alizapride is a dopamine antagonist.\", \"moa\": \"The anti-emetic action of Alizapride is due to its antagonist activity at D2 receptors in the chemoreceptor trigger zone (CTZ) in the central nervous system (CNS)\u00e2\u0080\u0094this action prevents nausea and vomiting triggered by most stimuli. Structurally similar to metoclopramide and, therefore, shares similar other atributres related to emesis and prokinetics.\", \"absorption\": \"None\", \"toxicity\": \"None\", \"halflife\": \"3 hours\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('50 MG/2ML', 'Intramuscular; Intravenous'), ('30 ML', ''), ('50 MG', ''), ('', ''), ('', ''), ('', 'Oral'), ('50 mg', 'Intramuscular; Intravenous'), ('12 mg', 'Oral'), ('50 mg', 'Oral')]\", \"properties\": \"[('logP', '1.81'), ('logS', '-2.8'), ('Water Solubility', '4.95e-01 g/l'), ('logP', '1.12'), ('IUPAC Name', '6-methoxy-N-{[1-(prop-2-en-1-yl)pyrrolidin-2-yl]methyl}-2H-1,2,3-benzotriazole-5-carboxamide'), ('Traditional IUPAC Name', 'alizapride'), ('Molecular Weight', '315.3702'), ('Monoisotopic Weight', '315.169524941'), ('SMILES', 'COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C'), ('Molecular Formula', 'C16H21N5O2'), ('InChI', 'InChI=1S/C16H21N5O2/c1-3-6-21-7-4-5-11(21)10-17-16(22)12-8-13-14(19-20-18-13)9-15(12)23-2/h3,8-9,11H,1,4-7,10H2,2H3,(H,17,22)(H,18,19,20)'), ('InChIKey', 'KSEYRUGYKHXGFW-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '83.14'), ('Refractivity', '89.21'), ('Polarizability', '33.92'), ('Rotatable Bond Count', '6'), ('H Bond Acceptor Count', '5'), ('H Bond Donor Count', '2'), ('pKa (strongest acidic)', '8.86'), ('pKa (strongest basic)', '7.77'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '1')]\", \"chEMBL\": \"1221\", \"pubChemCompound\": \"1140\", \"pubChemSubstance\": \"1255\", \"Clinical_status\": 2}}, {\"model\": \"drug.drug\", \"pk\": \"DB01616\", \"fields\": {\"drugtype\": 1, \"name\": \"Alverine\", \"groups\": \"1\", \"categories\": \"1310\", \"description\": \"Alverine is a smooth muscle relaxant used to relieve cramps or spasms of the stomach and intestines. It is therefore useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain.\", \"aliases\": \"\\n      |Alverine\", \"superclass\": \"9\", \"classname\": \"26\", \"subclass\": \"215\", \"direct_parent\": \"444\", \"indication\": \"Used to relieve cramps or spasms of the stomach and intestines. It is also useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain. Alverine citrate is also under investigation to increase the cytotoxic effects of the proteasome inhibitor MG132 on breast cancer cells. \", \"pharmacodynamics\": \"Alverine is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasms which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Diverticular disease is a condition in which small pouches form in the gut lining. These pouches can trap particles of food and become inflamed and painful. In irritable bowel syndrome the normal activity of the gut muscle is lost. The muscle spasms result in symptoms such as heartburn, abdominal pain and bloating, constipation or diarrhoea. By relaxing the gut muscle, alverine citrate relieves the symptoms of this condition. Alverine also relaxes the smooth muscle in the womb (uterus). It is therefore also used to treat painful menstruation, which is caused by muscle spasms in the uterus (dysmenorrhea).\", \"moa\": \"None\", \"absorption\": \"None\", \"toxicity\": \"Can produce hypotension and atropine-like toxic effects. Fatality has occurred following overdose with very high doses.\", \"halflife\": \"The plasma half-life averages 0.8 hours for alverine and 5.7 hours for the active primary metabolite.\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('', 'Oral'), ('60 mg', 'Oral'), ('', 'Oral')]\", \"properties\": \"[('logP', '5.73'), ('logS', '-5.5'), ('Water Solubility', '9.60e-04 g/l'), ('logP', '5.46'), ('IUPAC Name', 'ethylbis(3-phenylpropyl)amine'), ('Traditional IUPAC Name', 'alverine'), ('Molecular Weight', '281.4351'), ('Monoisotopic Weight', '281.214349869'), ('SMILES', 'CCN(CCCC1=CC=CC=C1)CCCC1=CC=CC=C1'), ('Molecular Formula', 'C20H27N'), ('InChI', 'InChI=1S/C20H27N/c1-2-21(17-9-15-19-11-5-3-6-12-19)18-10-16-20-13-7-4-8-14-20/h3-8,11-14H,2,9-10,15-18H2,1H3'), ('InChIKey', 'ZPFXAOWNKLFJDN-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '3.24'), ('Refractivity', '92.67'), ('Polarizability', '35.42'), ('Rotatable Bond Count', '9'), ('H Bond Acceptor Count', '1'), ('H Bond Donor Count', '0'), ('pKa (strongest basic)', '10.44'), ('Physiological Charge', '1'), ('Number of Rings', '2'), ('Bioavailability', '1'), ('Rule of Five', '0'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"1292\", \"pubChemCompound\": \"1217\", \"pubChemSubstance\": \"1332\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB01625\", \"fields\": {\"drugtype\": 1, \"name\": \"Isopropamide\", \"groups\": \"4\", \"categories\": \"452\", \"description\": \"Isopropamide iodide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.\", \"aliases\": \"Isopropamide|Stelabid No 2|Stelabid Forte|Stelabid No 1\", \"superclass\": \"9\", \"classname\": \"26\", \"subclass\": \"38\", \"direct_parent\": \"74\", \"indication\": \"For the treatment of a wide range of gastrointestinal disorders, including such conditions as peptic ulcer, gastritis, hyperchlorhydria, functional diarrhea, irritable or spastic colon, pyloroduodenal irritability, pylorospasm, acute nonspecific gastroenteritis, biliary dyskinesia and chronic cholelithiasis, duodenitis, gastrointestinal spasm; it may also be used to treat genitourinary spasm.\", \"pharmacodynamics\": \"Isopropamide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.\", \"moa\": \"Anticholinergics are a class of medications that inhibit parasympathetic nerve impulses by selectively blocking the binding of the neurotransmitter acetylcholine to its receptor in nerve cells. The nerve fibers of the parasympathetic system are responsible for the involuntary movements of smooth muscles present in the gastrointestinal tract. Inhibition here decreases acidity and motility, aiding in the treatment of gastrointestinal disorders.\", \"absorption\": \"None\", \"toxicity\": \"Symptoms of overdose include dryness of mouth, dysphagia, thirst, blurred vision, dilated pupils, photophobia, fever, rapid pulse and respiration, disorientation. Depression and circulatory collapse may result from severe overdosage.\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('', 'Oral')]\", \"properties\": \"[('logP', '2.27'), ('logS', '-7'), ('Water Solubility', '4.24e-05 g/l'), ('logP', '0.14'), ('IUPAC Name', '(3-carbamoyl-3,3-diphenylpropyl)(methyl)bis(propan-2-yl)azanium'), ('Traditional IUPAC Name', 'isopropamide'), ('Molecular Weight', '353.5209'), ('Monoisotopic Weight', '353.259288688'), ('SMILES', 'CC(C)[N+](C)(CCC(C(N)=O)(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C'), ('Molecular Formula', 'C23H33N2O'), ('InChI', 'InChI=1S/C23H32N2O/c1-18(2)25(5,19(3)4)17-16-23(22(24)26,20-12-8-6-9-13-20)21-14-10-7-11-15-21/h6-15,18-19H,16-17H2,1-5H3,(H-,24,26)/p+1'), ('InChIKey', 'JTPUMZTWMWIVPA-UHFFFAOYSA-O'), ('Polar Surface Area (PSA)', '43.09'), ('Refractivity', '120.74'), ('Polarizability', '41.28'), ('Rotatable Bond Count', '8'), ('H Bond Acceptor Count', '1'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '16.31'), ('pKa (strongest basic)', '-3.3'), ('Physiological Charge', '1'), ('Number of Rings', '2'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"1300\", \"pubChemCompound\": \"1225\", \"pubChemSubstance\": \"1340\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB04843\", \"fields\": {\"drugtype\": 1, \"name\": \"Mepenzolate\", \"groups\": \"0\", \"categories\": \"1806\", \"description\": \"Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.\", \"aliases\": \"Cantil|Mepenzolate\", \"superclass\": \"9\", \"classname\": \"26\", \"subclass\": \"38\", \"direct_parent\": \"74\", \"indication\": \"For use as adjunctive therapy in the treatment of peptic ulcer. It has not been \\r\\nshown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.\\r\\n\", \"pharmacodynamics\": \"Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor.\\r\\n\", \"moa\": \"Mepenzolate is a post-ganglionic parasympathetic inhibitor. It specifically antagonizes muscarinic receptors. This leads to decreases in gastric acid and pepsin secretion and suppression of spontaneous contractions of the colon.\", \"absorption\": \"Between 3 and 22% of an orally administered dose is excreted in the urine over a 5-day period, with the majority of the radioactivity appearing on Day 1. The remainder appears in the next 5 days in the feces and presumably has not been absorbed.\\r\\n\", \"toxicity\": \"The signs and symptoms of overdosage are headache; nausea; vomiting; blurred vision; dilated pupils; hot, dry skin; dizziness; dryness of the mouth; difficulty in swallowing; and CNS stimulation. A curare-like action may occur (i.e., neuromuscular blockade leading to muscular weakness and possible \\r\\nparalysis). The oral LD<sub>50</sub> is greater than 750 mg/kg in mice and greater than 1000 mg/kg in rats. \\r\\n\\r\\n\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('25 mg/1', 'Oral')]\", \"properties\": \"[('logP', '-1.1'), ('logS', '-5.8'), ('Water Solubility', '6.27e-04 g/l'), ('logP', '-0.97'), ('IUPAC Name', '3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1,1-dimethylpiperidin-1-ium'), ('Traditional IUPAC Name', 'mepenzolate'), ('Molecular Weight', '340.436'), ('Monoisotopic Weight', '340.191268703'), ('SMILES', 'C[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1'), ('Molecular Formula', 'C21H26NO3'), ('InChI', 'InChI=1S/C21H26NO3/c1-22(2)15-9-14-19(16-22)25-20(23)21(24,17-10-5-3-6-11-17)18-12-7-4-8-13-18/h3-8,10-13,19,24H,9,14-16H2,1-2H3/q+1'), ('InChIKey', 'GKNPSSNBBWDAGH-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '46.53'), ('Refractivity', '109.4'), ('Polarizability', '37.76'), ('Rotatable Bond Count', '5'), ('H Bond Acceptor Count', '2'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '11.05'), ('pKa (strongest basic)', '-4.5'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '0'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"2224\", \"pubChemCompound\": \"2831\", \"pubChemSubstance\": \"2948\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB04885\", \"fields\": {\"drugtype\": 1, \"name\": \"Cilansetron\", \"groups\": \"24\", \"categories\": \"1837\", \"description\": \"Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.\", \"aliases\": \"\\n      |Cilansetron\", \"superclass\": \"4\", \"classname\": \"18\", \"subclass\": \"164\", \"direct_parent\": \"310\", \"indication\": \"For the treatment of symptoms associated with irritable bowel syndrome.\", \"pharmacodynamics\": \"Cilansetron is an orally formulated medication that blocks the action of 5-hydroxy-tryptamine 3 (5-HT3) receptors. Phase III studies of cilansetron had been suspended by Solvay in order to assess whether the drug possesses safety concerns similar to alosetron. Alosetron, also a 5-HT3 antagonist, was withdrawn from the market due to questions regarding its safety. Phase III testing with cilansetron has since resumed. In June 2005 the company announced that they were reviewing the priority of the cilansetron program.\", \"moa\": \"Cilansetron is a potent and selective 5-HT<sub>3</sub> receptor antagonist. 5-HT<sub>3</sub> receptors are nonselective cation channels that are extensively distributed on enteric neurons in the human gastrointestinal tract, as well as other peripheral and central locations. Activation of these channels and the resulting neuronal depolarization affect the regulation of visceral pain, colonic transit and gastrointestinal secretions, processes that relate to the pathophysiology of irritable bowel syndrome (IBS). 5-HT<sub>3</sub> receptor antagonists such as cilansetron inhibit activation of non-selective cation channels which results in the modulation of the enteric nervous system.\", \"absorption\": \"Rapidly absorbed orally with a bioavailability of greater than 80% in rats.\", \"toxicity\": \"None\", \"halflife\": \"The elimination half-life after 4- and 8-mg oral doses administered 3 times daily for 6 days was reported to be 1.6 to 1.9 hours.\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[]\", \"properties\": \"[('logP', '2.47'), ('logS', '-3.4'), ('Water Solubility', '1.15e-01 g/l'), ('logP', '2.83'), ('IUPAC Name', '(12R)-12-[(2-methyl-1H-imidazol-1-yl)methyl]-1-azatetracyclo[7.6.1.0\u00e2\u0081\u00b5,\u00c2\u00b9\u00e2\u0081\u00b6.0\u00c2\u00b9\u00e2\u0081\u00b0,\u00c2\u00b9\u00e2\u0081\u00b5]hexadeca-5(16),6,8,10(15)-tetraen-11-one'), ('Traditional IUPAC Name', 'cilansetron'), ('Molecular Weight', '319.4002'), ('Monoisotopic Weight', '319.168462309'), ('SMILES', 'CC1=NC=CN1C[C@H]1CCC2=C(C3=CC=CC4=C3N2CCC4)C1=O'), ('Molecular Formula', 'C20H21N3O'), ('InChI', 'InChI=1S/C20H21N3O/c1-13-21-9-11-22(13)12-15-7-8-17-18(20(15)24)16-6-2-4-14-5-3-10-23(17)19(14)16/h2,4,6,9,11,15H,3,5,7-8,10,12H2,1H3/t15-/m1/s1'), ('InChIKey', 'NCNFDKWULDWJDS-OAHLLOKOSA-N'), ('Polar Surface Area (PSA)', '39.82'), ('Refractivity', '94.69'), ('Polarizability', '35.88'), ('Rotatable Bond Count', '2'), ('H Bond Acceptor Count', '2'), ('H Bond Donor Count', '0'), ('pKa (strongest acidic)', '15.48'), ('pKa (strongest basic)', '7.34'), ('Physiological Charge', '1'), ('Number of Rings', '5'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"2262\", \"pubChemCompound\": \"2869\", \"pubChemSubstance\": \"2986\", \"Clinical_status\": 2}}, {\"model\": \"drug.drug\", \"pk\": \"DB04924\", \"fields\": {\"drugtype\": 1, \"name\": \"Itopride\", \"groups\": \"24\", \"categories\": \"1859\", \"description\": \"Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.\", \"aliases\": \"\\n      |Itopride\", \"superclass\": \"9\", \"classname\": \"26\", \"subclass\": \"50\", \"direct_parent\": \"472\", \"indication\": \"Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous).\", \"pharmacodynamics\": \"None\", \"moa\": \"Itopride has anticholinesterase (AchE) activity as well as dopamine D2 receptor antagonistic activity. It is well established that M3 receptors exist on the smooth muscle layer throughout the gut and acetylcholine (ACh) released from enteric nerve endings stimulates the contraction of smooth muscle through M3 receptors. The enzyme AChE hydrolyses the released ACh, inactivates it and thus inhibits the gastric motility leading to various digestive disorders. Besides ACh, dopamine is present in significant amounts in the gastrointestinal tract and has several inhibitory effects on gastrointestinal motility, including reduction of lower esophageal sphincter and intragastric pressure. These effects appear to result from suppression of ACh release from the myenteric motor neurons and are mediated by the D2 subtype of dopamine receptors. Itopride, by virtue of its dopamine D2 receptor antagonism, removes the inhibitory effects on Ach release. It also inhibits the enzyme AchE which prevents the degradation of ACh. The net effect is an increase in ACh concentration, which in turn, promotes gastric motility, increases the lower esophageal sphincter pressure, accelerates gastric emptying and improves gastro-duodenal coordination. This dual mode of action of Itopride is unique and different from the actions of other prokinetic agents available in the market.\\r\\n\", \"absorption\": \"None\", \"toxicity\": \"None\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('', 'Oral'), ('50 mg', 'Oral'), ('', ''), ('50 mg', 'Oral')]\", \"properties\": \"[('logP', '2.41'), ('logS', '-4.1'), ('Water Solubility', '2.61e-02 g/l'), ('logP', '2.32'), ('IUPAC Name', 'N-({4-[2-(dimethylamino)ethoxy]phenyl}methyl)-3,4-dimethoxybenzamide'), ('Traditional IUPAC Name', 'itopride'), ('Molecular Weight', '358.4314'), ('Monoisotopic Weight', '358.18925733'), ('SMILES', 'COC1=CC=C(C=C1OC)C(=O)NCC1=CC=C(OCCN(C)C)C=C1'), ('Molecular Formula', 'C20H26N2O4'), ('InChI', 'InChI=1S/C20H26N2O4/c1-22(2)11-12-26-17-8-5-15(6-9-17)14-21-20(23)16-7-10-18(24-3)19(13-16)25-4/h5-10,13H,11-12,14H2,1-4H3,(H,21,23)'), ('InChIKey', 'QQQIECGTIMUVDS-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '60.03'), ('Refractivity', '102.05'), ('Polarizability', '40.58'), ('Rotatable Bond Count', '9'), ('H Bond Acceptor Count', '5'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '14.71'), ('pKa (strongest basic)', '8.77'), ('Physiological Charge', '1'), ('Number of Rings', '2'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"2280\", \"pubChemCompound\": \"2888\", \"pubChemSubstance\": \"3010\", \"Clinical_status\": 2}}, {\"model\": \"drug.drug\", \"pk\": \"DB06706\", \"fields\": {\"drugtype\": 1, \"name\": \"Isometheptene\", \"groups\": \"0\", \"categories\": \"2310\", \"description\": \"Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.\", \"aliases\": \"Isometheptene Mucate, Dichloralphenazone, and Acetaminophen|LarkaDrin|Nodolor|Isometheptene|MigraTen|Prodrin|Isometheptene Mucate/Dichloralphenazone/Acetaminophen|Isometheptene Mucate, Caffeine, and Acetaminophen|Isometheptene Mucate, Caffeine, Acetaminophen|\\n      |Isometheptene-Dichloral-APAP Oral\", \"superclass\": \"6\", \"classname\": \"10\", \"subclass\": \"10\", \"direct_parent\": \"16\", \"indication\": \"Isometheptene is a sympathomimetic drug which causes vasoconstriction. It is used for treating migraines and tension headaches.\", \"pharmacodynamics\": \"Isometheptene Mucate is an indirect-acting sympathomimetic. Due to its vasoconstricting properties, Isometheptene Mucate is used for the treatment of acute migraine attacks, usually in combination with other analgeics. It can also displace catecholamines from vesicles inside the neuron leading to the sympathetic responses it is known for.\", \"moa\": \"Isometheptene's vasoconstricting properties arise through activation of the sympathetic nervous system via epinephrine and norepinephrine (or their molecular analogues as is the case with this drug). These compounds elicites smooth muscle activation leading to vasoconstriction. These compounds interact with cell surface adrenergic receptors. Such stimuli result in a signal transduction cascade that leads to increased intracellular calcium from the sarcoplasmic reticulum through IP3 mediated calcium release, as well as enhanced calcium entry across the sarcolemma through calcium channels. The rise in intracellular calcium complexes with calmodulin, which in turn activates myosin light chain kinase. This enzyme is responsible for phosphorylating the light chain of myosin to stimulate cross bridge cycling.\\r\\n\\r\\nOnce elevated, the intracellular calcium concentration is returned to its basal level through a variety of protein pumps and calcium exchangers located on the plasma membrane and sarcoplasmic reticulum. This reduction in calcium removes the stimulus necessary for contraction allowing for a return to baseline. The drug can also cause vesicular displacement of noradrenaline from the neuron into the synapse with a similar effect as tyramine.\", \"absorption\": \"None\", \"toxicity\": \"None\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('30 mg', 'Oral'), ('30 mg', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('', 'Oral')]\", \"properties\": \"[('logP', '2.07'), ('logS', '-1.7'), ('Water Solubility', '3.06e+00 g/l'), ('logP', '2.32'), ('IUPAC Name', 'methyl(6-methylhept-5-en-2-yl)amine'), ('Traditional IUPAC Name', 'isometheptene'), ('Molecular Weight', '141.2539'), ('Monoisotopic Weight', '141.151749613'), ('SMILES', 'CNC(C)CCC=C(C)C'), ('Molecular Formula', 'C9H19N'), ('InChI', 'InChI=1S/C9H19N/c1-8(2)6-5-7-9(3)10-4/h6,9-10H,5,7H2,1-4H3'), ('InChIKey', 'XVQUOJBERHHONY-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '12.03'), ('Refractivity', '47.59'), ('Polarizability', '18.81'), ('Rotatable Bond Count', '4'), ('H Bond Acceptor Count', '1'), ('H Bond Donor Count', '1'), ('pKa (strongest basic)', '10.67'), ('Physiological Charge', '1'), ('Number of Rings', '0'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '0'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"2650\", \"pubChemCompound\": \"3149\", \"pubChemSubstance\": \"3506\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB06751\", \"fields\": {\"drugtype\": 1, \"name\": \"Drotaverine\", \"groups\": \"1\", \"categories\": \"2342\", \"description\": \"Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4).[A231619] It is a benzylisoquinoline derivative that is structurally related to [papaverine], although it displays more potent antispasmodic activities than papaverine. Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and vasomotor diseases associated with smooth muscle spasms.[A7036] It also has been investigated in dysmenorrhea, abortion, [A231609] and augmentation of labour.[A231614] More recently, drotaverine gained attention in the treatment of benign prostatic hyperplasia, parainfluenza, and avian influenza viruses.[A231619]\\r\\n\\r\\nDrotaverine is not approved by the FDA, European Medicines Agency, or Health Canada. It is approved for use in Thailand as oral tablets or intramuscular injections.[L22689]\", \"aliases\": \"\\n      |Drotaverine\", \"superclass\": \"4\", \"classname\": \"112\", \"subclass\": \"1\", \"direct_parent\": \"294\", \"indication\": \"Drotaverine is used to alleviate gastrointestinal and genitourinary smooth muscle spasms, such as cholecystitis and gallbladder disorders.[L22689]\", \"pharmacodynamics\": \"Drotaverine is an e spasmolytic agent with a relaxing effect on smooth muscles. It works to relieve visceral spasms and improve cervical dilation. _In vitro_, drotaverine mediated cytostatic effects on several human tumor cell lines and nonmalignant mouse fibroblasts.[A231619] Drotaverine may have minor allosteric calcium channel blocking properties: _in vitro_, drotaverine behaves like voltage-dependent L-type calcium channel blockers.[A231624]\", \"moa\": \"Drotaverine is a selective inhibitor of phosphodiesterase 4 (PDE4), which is an enzyme responsible for the degradation of cyclic adenosine monophosphate (cAMP). Inhibition of PDE4 leads to elevated levels of cAMP, leading to smooth muscle relaxation. Recent research showed that low levels of cAMP have been associated with brain tumorigenesis, leading to the investigation of PDE4 inhibitors as potential anticancer agents.[A231619]\", \"absorption\": \"Drotaverine is not completely absorbed following oral administration and its bioavailability is highly variable. Following oral administration of a single 80 mg dose, the absolute bioavailability ranged between 24.5 and 91 % with a mean of 58.2 \u00c2\u00b1 18.2%. Mean C<sub>max</sub> was 292 \u00c2\u00b1 88 ng/mL. Mean AUC was 3251 \u00c2\u00b1 950 ng*h/mL. Mean T<sub>max</sub> was 1.9 \u00c2\u00b1 0.54 hours.[A7036]\", \"toxicity\": \"Oral LD<sub>50</sub> is 540 mg/kg in rats and 350 mg/kg in mice.[L32499] There is limited information on drotaverine overdose and toxicity.\", \"halflife\": \"Following oral administration of a single 80 mg dose, the mean half-life was 9.11 \u00c2\u00b1 1.29 hours. Following an intravenous dose of 80 mg, the mean half-life 9.33 \u00c2\u00b1 1.02 hours.[A7036]\", \"distribution_volume\": \"Following oral administration of a single 80 mg dose, the mean volume of distribution was 193 \u00c2\u00b1 48 L. Following an intravenous dose of 80 mg, the mean volume of distribution was 195 \u00c2\u00b1 48 L.[A7036]\", \"protein_binding\": \"There is no information available.\", \"dosages\": \"[('20 mg/1ml', ''), ('', 'Oral'), ('40 mg', 'Oral'), ('40 mg', 'Oral')]\", \"properties\": \"[('logP', '5.35'), ('logS', '-5.3'), ('Water Solubility', '2.00e-03 g/l'), ('logP', '4.19'), ('IUPAC Name', '(1Z)-1-[(3,4-diethoxyphenyl)methylidene]-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline'), ('Traditional IUPAC Name', 'drotaverine'), ('Molecular Weight', '397.5072'), ('Monoisotopic Weight', '397.225308485'), ('SMILES', 'CCOC1=C(OCC)C=C(\\\\\\\\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1'), ('Molecular Formula', 'C24H31NO4'), ('InChI', 'InChI=1S/C24H31NO4/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20/h9-10,13-16,25H,5-8,11-12H2,1-4H3/b20-13-'), ('InChIKey', 'OMFNSKIUKYOYRG-MOSHPQCFSA-N'), ('Polar Surface Area (PSA)', '48.95'), ('Refractivity', '117.99'), ('Polarizability', '46.99'), ('Rotatable Bond Count', '9'), ('H Bond Acceptor Count', '5'), ('H Bond Donor Count', '1'), ('pKa (strongest basic)', '7.4'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '1')]\", \"chEMBL\": \"2682\", \"pubChemCompound\": \"3178\", \"pubChemSubstance\": \"3538\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB06787\", \"fields\": {\"drugtype\": 1, \"name\": \"Hexocyclium\", \"groups\": \"0\", \"categories\": \"2366\", \"description\": \"Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. It was once available under the tradename Tral marketed by Abbvie Inc. but has been discontinued. Proton pump inhibitors like [DB00338] and opiate anti-diarrheal agents like [DB00836] have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more favorable side effect profiles.\", \"aliases\": \"\\n      |Hexocyclium\", \"superclass\": \"6\", \"classname\": \"10\", \"subclass\": \"10\", \"direct_parent\": \"170\", \"indication\": \"The World Health Organization classifies hexocyclium as a drug for functional gastrointestinal disorders [L876]. Like other anti-muscarinic agents, hexocyclium was likely used to treat peptic ulcers or diarrhea.\", \"pharmacodynamics\": \"Hexocyclium reduces gastrointesitinal motility and gastric acid secretion [A19711, A19712].\", \"moa\": \"Hexocyclium binds to and inhibits muscarinic acetylcholine receptors [A19700]. This decreases gastric acid secretion by preventing the activation of M3 receptors on pareital cells and subsequent stimulation of gastric acid secretion [T28]. The antagonism of M3 receptors in the intestine inhibits smooth muscle contraction resulting in a decrease in motility. The binding of hexocyclium to other muscarinic receptor types produces typical anti-muscarinic side effects.\", \"absorption\": \"None\", \"toxicity\": \"None\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[]\", \"properties\": \"[('logP', '-1.1'), ('logS', '-5.8'), ('Water Solubility', '5.76e-04 g/l'), ('logP', '-0.99'), ('IUPAC Name', '4-(2-cyclohexyl-2-hydroxy-2-phenylethyl)-1,1-dimethylpiperazin-1-ium'), ('Traditional IUPAC Name', 'hexocyclum'), ('Molecular Weight', '317.496'), ('Monoisotopic Weight', '317.258740111'), ('SMILES', 'C[N+]1(C)CCN(CC(O)(C2CCCCC2)C2=CC=CC=C2)CC1'), ('Molecular Formula', 'C20H33N2O'), ('InChI', 'InChI=1S/C20H33N2O/c1-22(2)15-13-21(14-16-22)17-20(23,18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3,5-6,9-10,19,23H,4,7-8,11-17H2,1-2H3/q+1'), ('InChIKey', 'ZRYHPQCHHOKSMD-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '23.47'), ('Refractivity', '108.16'), ('Polarizability', '38.29'), ('Rotatable Bond Count', '4'), ('H Bond Acceptor Count', '2'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '13.51'), ('pKa (strongest basic)', '4.95'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '0'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"2703\", \"pubChemCompound\": \"3196\", \"pubChemSubstance\": \"3560\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB08810\", \"fields\": {\"drugtype\": 1, \"name\": \"Cinitapride\", \"groups\": \"24\", \"categories\": \"2489\", \"description\": \"Cinitapride is a gastroprokinetic agent and antiulcer benzamide with agonist activity at 5-HT1 and 5-HT4 receptors and antagonist activity at 5-HT2 receptors. It is marketed in Spain and Mexico.\", \"aliases\": \"\\n      |Cinitapride\", \"superclass\": \"9\", \"classname\": \"26\", \"subclass\": \"107\", \"direct_parent\": \"577\", \"indication\": \"It is indicated to treat gastrointestinal disorders associated with motility disturbances like gastroesophageal reflux disease (GERD), non-ulcer dyspepsia and delayed gastric emptying.\", \"pharmacodynamics\": \"None\", \"moa\": \"Cinitapride is a substituted benzamide with 5-HT receptor antagonist and agonist activity.\", \"absorption\": \"The absorption of cinitapride (12mg) following oral administration was rapid, with peak levels being achieved 2 h after dosing; absorption following intramuscular administration (4mg) was even more rapid, with peak levels (50% more that oral levels) being achieved 1 h after dosing.\", \"toxicity\": \"The symptoms of overdose include drowsiness, confusion and extrapyramidal effects. \", \"halflife\": \"3-5 h during the first 8 h and a residual half-life greater than 15 h thereafter.\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('1 mg', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('20 mg', 'Oral'), ('', 'Oral')]\", \"properties\": \"[('logP', '3.7'), ('logS', '-4.4'), ('Water Solubility', '1.41e-02 g/l'), ('logP', '2.79'), ('IUPAC Name', '4-amino-N-{1-[(cyclohex-3-en-1-yl)methyl]piperidin-4-yl}-2-ethoxy-5-nitrobenzamide'), ('Traditional IUPAC Name', '[(1R,2R,6R,10S,11R,15R,17R)-13-benzyl-6-hydroxy-4,17-dimethyl-5-oxo-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0^{1,10}.0^{2,6}.0^{11,15}]octadeca-3,8-dien-8-yl]methyl 2-(4-hydroxy-3-methoxyphenyl)acetate'), ('Molecular Weight', '402.4873'), ('Monoisotopic Weight', '402.226705468'), ('SMILES', 'CCOC1=CC(N)=C(C=C1C(=O)NC1CCN(CC2CCC=CC2)CC1)[N+]([O-])=O'), ('Molecular Formula', 'C21H30N4O4'), ('InChI', 'InChI=1S/C21H30N4O4/c1-2-29-20-13-18(22)19(25(27)28)12-17(20)21(26)23-16-8-10-24(11-9-16)14-15-6-4-3-5-7-15/h3-4,12-13,15-16H,2,5-11,14,22H2,1H3,(H,23,26)'), ('InChIKey', 'ZDLBNXXKDMLZMF-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '110.73'), ('Refractivity', '114.58'), ('Polarizability', '44.37'), ('Rotatable Bond Count', '7'), ('H Bond Acceptor Count', '6'), ('H Bond Donor Count', '2'), ('pKa (strongest acidic)', '13.62'), ('pKa (strongest basic)', '9.74'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '1')]\", \"chEMBL\": \"3564\", \"pubChemCompound\": \"4558\", \"pubChemSubstance\": \"4924\", \"Clinical_status\": 2}}, {\"model\": \"drug.drug\", \"pk\": \"DB09018\", \"fields\": {\"drugtype\": 1, \"name\": \"Bromopride\", \"groups\": \"24\", \"categories\": \"2598\", \"description\": \"Bromopride is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.\", \"aliases\": \"\\n      |Bromopride\", \"superclass\": \"9\", \"classname\": \"29\", \"subclass\": \"203\", \"direct_parent\": \"409\", \"indication\": \"Bromopride in indicated in the treatment of nausea and vomiting, including PONV (post-operative nausea and vomiting), gastroesophageal reflux disease (GERD/GORD), as well as endoscopy preparation and radiographic studies of the GI tract. \", \"pharmacodynamics\": \"None\", \"moa\": \"None\", \"absorption\": \"None\", \"toxicity\": \"None\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"40%.\", \"dosages\": \"[('4 mg', 'Oral'), ('1 mg', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('', ''), ('', ''), ('', 'Intramuscular; Intravenous'), ('', '')]\", \"properties\": \"[('logP', '2.36'), ('logS', '-3.2'), ('Water Solubility', '2.41e-01 g/l'), ('logP', '1.56'), ('IUPAC Name', '4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide'), ('Traditional IUPAC Name', 'bromopride'), ('Molecular Weight', '344.247'), ('Monoisotopic Weight', '343.08953961'), ('SMILES', 'CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC'), ('Molecular Formula', 'C14H22BrN3O2'), ('InChI', 'InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)'), ('InChIKey', 'GIYAQDDTCWHPPL-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '67.59'), ('Refractivity', '86.34'), ('Polarizability', '33.92'), ('Rotatable Bond Count', '7'), ('H Bond Acceptor Count', '4'), ('H Bond Donor Count', '2'), ('pKa (strongest acidic)', '14.58'), ('pKa (strongest basic)', '9.04'), ('Physiological Charge', '1'), ('Number of Rings', '1'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"3673\", \"pubChemCompound\": \"4654\", \"pubChemSubstance\": \"5030\", \"Clinical_status\": 2}}, {\"model\": \"drug.drug\", \"pk\": \"DB09089\", \"fields\": {\"drugtype\": 1, \"name\": \"Trimebutine\", \"groups\": \"0\", \"categories\": \"2648\", \"description\": \"Trimebutine is a spasmolytic agent that regulates intestinal and colonic motility and relieves abdominal pain with antimuscarinic and weak mu opioid agonist effects. It is marketed for the treatment of irritable bowel syndrome (IBS) and lower gastrointestinal tract motility disorders, with IBS being one of the most common multifactorial GI disorders [A19691]. It is used to restore normal bowel function and is commonly present in pharmaceutical mixtures as trimebutine maleate salt form. Trimebutine is not a FDA-approved drug, but it is available in Canada and several other international countries.\", \"aliases\": \"Trimebutine|\\n      |Modulon Tab 100mg|Modulon|Modulon Inj 50mg/5ml\", \"superclass\": \"9\", \"classname\": \"26\", \"subclass\": \"50\", \"direct_parent\": \"922\", \"indication\": \"Indicated for symptomatic treatment of irritable bowel syndrome (IBS) and treatment of postoperative paralytic ileus following abdominal surgery. \", \"pharmacodynamics\": \"Trimebutine is a spasmolytic agent that acts directly on smooth muscle to modulate gastric motility. It shows a \\\"dual function\\\" that stimulates or inhibits spontaneous contractions depending on the concentration and prior contractile activity in the preparation. Targeting ion conductance that regulates GI motility, trimebutine inhibits the inward calcium currents and calcium-dependent potassium currents in a concentration-dependent manner [A19691]. At lower concentrations (1-10uM), trimebutine depolarizes the resting membrane potential without affecting the amplitude of contractions, which is thought to be mediated by inhibition of outward potassium currents. It is also shown to activate T-type Ca2+ channel and increase gastric emptying, intestinal and colonic contractility [A19690]. At higher concentrations (100-300uM), reduced amplitude of spontaneous contractions and action potentials is thought to be mediated by inhibition of L-type Ca2+ channels and inward calcium current [A19691]. Trimebutine mediates a local anesthetic action by acting as a weak agonist at mu opioid receptors.\", \"moa\": \"At high concentrations, trimebutine is shown to inhibit the extracellular Ca2+ influx in the smooth muscle cells through voltage dependent L-type Ca2+ channels and further Ca2+ release from intracellular Ca2+ stores [A19691, A19689]. Trimebutine is suggested to bind to the inactivated state of the calcium channel with high affinity. Reduced calcium influx attenuates membrane depolarization and decrease colon peristalsis. It also inhibits outward K+ currents in response to membrane depolarization of the GI smooth muscle cells at resting conditions through inhibition of delayed rectifier K+ channels and Ca2+ dependent K+ channels, which results in induced muscle contractions [A19691, A19695]. Trimebutine binds to mu opioid receptors with more selectivity compared to delta or kappa opioid receptors but with lower affinity than their natural ligands. Its metabolites (N-monodesmethyl-trimebutine or nor-trimebutine), are also shown to bind to opoid receptors on brain membranes and myenteric synaptosomes [A19692]. \", \"absorption\": \"The free base form or salt form of trimebutine are rapidly absorbed after oral administration, with the peak plasma concentration reached after 1 hour of ingestion [A19692]. The time to reach peak plasma concentration following a single oral dose of 200mg trimebutine is 0.80 hours [L872].\", \"toxicity\": \"Common gastrointestinal adverse effects include dry mouth, foul taste, diarrhea, dyspepsia, epigastric pain, nausea and constipation. Some CNS effects include drowsiness, fatigue, dizziness, hot/cold sensations and headaches. In case of overdosage, gastric lavage is recommended. Oral LD50 in mouse and rats is >5000 mg/kg and 2500 mg/kg in rabbits, respectively. Trimebutine is not reported to display teratogenic, mutagenic or carcinogenic potential [L872].\", \"halflife\": \"The elimination half life is approximately 1 hour following a single oral dose of 2mg/kg [A19692], and 2.77 hours following a single oral dose 200 mg [L872].\", \"distribution_volume\": \"Trimebutine is most likely to be accumulated in the stomach and the intestinal walls in highest concentrations. The fetal transfer is reported to be low [A19692]. \", \"protein_binding\": \"Protein binding is minimal with 5% in vivo and in vitro to serum albumin [L872]. \", \"dosages\": \"[('100 mg', 'Oral'), ('300 mg', 'Oral'), ('', ''), ('72 MG/15ML', 'Oral'), ('', 'Intravenous'), ('', ''), ('', 'Oral'), ('', 'Oral'), ('0.787 g/100g', 'Oral'), ('50 mg', 'Intramuscular'), ('100 mg', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('300 mg', 'Oral'), ('300 mg', 'Oral'), ('', 'Oral'), ('1.333 g', 'Oral'), ('200 mg', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('1.334 g', 'Oral'), ('', ''), ('10 mg / 1 mL', 'Intramuscular; Intravenous'), ('200 mg', 'Oral'), ('300 mg', 'Oral'), ('', 'Oral'), ('', 'Rectal'), ('', 'Rectal'), ('10 mg', 'Rectal'), ('200 mg', 'Oral'), ('200 mg', 'Oral'), ('300 mg', 'Oral'), ('', 'Oral'), ('50 mg', 'Intramuscular; Intravenous'), ('1.33 g', 'Oral')]\", \"properties\": \"[('logP', '3.94'), ('logS', '-4.3'), ('Water Solubility', '1.90e-02 g/l'), ('logP', '4.11'), ('IUPAC Name', '2-(dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoate'), ('Traditional IUPAC Name', 'trimebutine'), ('Molecular Weight', '387.476'), ('Monoisotopic Weight', '387.204573038'), ('SMILES', 'CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1'), ('Molecular Formula', 'C22H29NO5'), ('InChI', 'InChI=1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3'), ('InChIKey', 'LORDFXWUHHSAQU-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '57.23'), ('Refractivity', '108.94'), ('Polarizability', '42.43'), ('Rotatable Bond Count', '10'), ('H Bond Acceptor Count', '5'), ('H Bond Donor Count', '0'), ('pKa (strongest basic)', '8.48'), ('Physiological Charge', '1'), ('Number of Rings', '2'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"3720\", \"pubChemCompound\": \"4691\", \"pubChemSubstance\": \"5076\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB09090\", \"fields\": {\"drugtype\": 1, \"name\": \"Pinaverium\", \"groups\": \"0\", \"categories\": \"2649\", \"description\": \"Pinaverium is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. It is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders [A19697] and may be considered as effective first-lline therapy for patients with irritable bowel syndrome (IBS) [A19702]. Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada.\", \"aliases\": \"\\n      |Pinaverium|Dicetel\", \"superclass\": \"7\", \"classname\": \"15\", \"subclass\": \"142\", \"direct_parent\": \"270\", \"indication\": \"Pinaverium is indicated for the symptomatic treatment of irritable bowel syndrome (IBS) and functional disorders of the biliary tract.\", \"pharmacodynamics\": \"Pinaverium is a selective and specific voltage-dependent calcium channel blocker located on intestinal smooth muscle cells to inhibit calcium influx. It mediates various effects on the GI tract: it causes oesophageal, gastric and duodenal relaxation, relaxes the colon and intestines, inhibits colonic motility in response to food, hormonal or pharmacological stimuli, accelerates gastric emptying, and reduces contractions of the gallbladder and phasic contractions of sphincter of Oddi [L873, A19702]. At higher concentrations, pinaverium also exhibits very weak anticholinergic effects [L873] but is not shown to display vasodilatory or anti-arrythmic actions [T37]. \", \"moa\": \"Pinaverium interacts with the 1,4-dihydropyridine binding sites on voltage dependent L-type calcium channels located on GI smooth muscle cells in a competitve manner [A19698]. The binding site is located in the alpha 1S subunit and pinaverium most likely antagonizes the action of calcium ions by stabilizing a non-conducting channel state [A19705]. Pinaverium inhibits smooth muscle contractions of the GI tract by inhibiting inward calcium current and calcium influx. It is suggested that pinaverium may be able to bind to both closed or inactivates states of the calcium channel with similar affinity [T37, A19697]. \", \"absorption\": \"After oral administration, pinaverium is poorly absorbed (5-10%) followed by uptake by liver. Poor absorption is due to its highly polar quaternary ammonium group and high molecular weight [L873], which limits extensive diffusion across all cell membranes and promotes its selectivity towards the gastrointestinal tracts []. Peak plasma concentration is reached within one hour after administration and the absolute oral bioavailability is reported to be less than 1%. \", \"toxicity\": \"Some minor GI-related adverse effects include epigastric pain and/or fullness, nausea, constipation, heartburn, distension, and diarrhoea. Other side effects are headache, dry mouth, drowsiness, vertigo and skin allergy. Oral LD50 in mice, rats and rabbits are 1531 mg/kg, 1145 mg/kg and 154 mg/kg, respectively [L873]. Pinaverium displays no teratogenic, mutagenic or carcinogenic potential. \", \"halflife\": \"The mean elimination half life is approximately 1.5 hours [L873]. \", \"distribution_volume\": \"It is selectively distributed to the digestive tract due to poor absorption and marked hepatobiliary excretion [L873].\", \"protein_binding\": \"Pinaverium is highly bound to human plasma proteins with the ratio of 97% [L873].\", \"dosages\": \"[('', 'Oral'), ('100 mg', 'Oral'), ('', ''), ('', 'Oral'), ('50 mg', 'Oral'), ('', 'Oral'), ('50 mg', 'Oral'), ('', 'Oral'), ('', 'Oral'), ('100 mg', 'Oral'), ('100 mg', 'Oral')]\", \"properties\": \"[('logP', '3.71'), ('logS', '-8.2'), ('Water Solubility', '3.42e-06 g/l'), ('logP', '0.67'), ('IUPAC Name', '4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-(2-{6,6-dimethylbicyclo[3.1.1]heptan-2-yl}ethoxy)ethyl]morpholin-4-ium'), ('Traditional IUPAC Name', '4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-(2-{6,6-dimethylbicyclo[3.1.1]heptan-2-yl}ethoxy)ethyl]morpholin-4-ium'), ('Molecular Weight', '511.52'), ('Monoisotopic Weight', '510.221348'), ('SMILES', 'COC1=C(OC)C=C(C[N+]2(CCOCCC3CCC4CC3C4(C)C)CCOCC2)C(Br)=C1'), ('Molecular Formula', 'C26H41BrNO4'), ('InChI', 'InChI=1S/C26H41BrNO4/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27/h15,17,19,21-22H,5-14,16,18H2,1-4H3/q+1'), ('InChIKey', 'DDHUTBKXLWCZCO-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '36.92'), ('Refractivity', '143.32'), ('Polarizability', '54.41'), ('Rotatable Bond Count', '10'), ('H Bond Acceptor Count', '4'), ('H Bond Donor Count', '0'), ('pKa (strongest acidic)', '17.16'), ('pKa (strongest basic)', '-3.8'), ('Physiological Charge', '1'), ('Number of Rings', '4'), ('Bioavailability', '1'), ('Rule of Five', '0'), ('Ghose Filter', '0'), ('MDDR-Like Rule', '1')]\", \"chEMBL\": \"3721\", \"pubChemCompound\": \"4692\", \"pubChemSubstance\": \"5077\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB09300\", \"fields\": {\"drugtype\": 1, \"name\": \"Butylscopolamine\", \"groups\": \"6\", \"categories\": \"2763\", \"description\": \"Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it does not directly affect pain, but rather works to prevent painful cramps and spasms from occurring. It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.\", \"aliases\": \"Butylscopolamine|Accel-hyoscine|Hyoscine Butylbromide Injection Sandoz Standard|Buscopan|Buscopan Sup 10mg|Hyoscine Butylbromide Injection BP\", \"superclass\": \"2\", \"classname\": \"2\", \"subclass\": \"1\", \"direct_parent\": \"2\", \"indication\": \"Used to treat abdmoninal cramping and pain [FDA Label].\", \"pharmacodynamics\": \"Scopolamine butylbromide is a muscarinic antagonist which acts to prevent acetylcholine-stimulated contraction of smooth muscle in the gastrointestinal tract [A7905].\", \"moa\": \"Scopolamine butylbromide binds to muscarinic M3 receptors in the gastrointestinal tract [A7905]. This prevents acetycholine from binding to and activating the receptors which would result in contraction of the smooth muscle. The inhibition of contraction reduces spasms and their related pain during abdominal cramping.\", \"absorption\": \"Scopolamine butylbromide has extremely low oral bioavailability with only 0.25-0.82% reaching systemic circulation [A7905]. Peak plasma concentration is reached 0.25-2 hours. Scopolamine butylbromide does not cross the blood brain barrier.\", \"toxicity\": \"None\", \"halflife\": \"The half life of elimination is 1-5 hours [A7905].\", \"distribution_volume\": \"The volume of distribution is 128 liters [A7905].\", \"protein_binding\": \"None\", \"dosages\": \"[('20 MG/ML', 'Intramuscular; Intravenous'), ('10 mg', 'Oral'), ('20 mg/ml', 'Parenteral'), ('', 'Intramuscular; Intravenous'), ('10 MG', 'Rectal'), ('10 mg/1', 'Oral'), ('', 'Oral'), ('', 'Rectal'), ('', ''), ('', 'Rectal'), ('', 'Oral'), ('500 MG', 'Oral'), ('10 mg / sup', 'Rectal'), ('', 'Intramuscular; Intravenous; Subcutaneous'), ('20 MG/ML', ''), ('20 MG/1ML', ''), ('10.00 mg', 'Oral'), ('20 mg/ml', 'Intramuscular; Intravenous'), ('', 'Parenteral'), ('5 mg', 'Oral'), ('', 'Parenteral'), ('', 'Oral'), ('', 'Oral'), ('100 mg', 'Oral'), ('', 'Oral'), ('10 mg', 'Oral'), ('', 'Oral'), ('10 mg', 'Oral'), ('20 mg/ml', 'Intramuscular; Intravenous; Subcutaneous'), ('', 'Intramuscular; Intravenous; Subcutaneous'), ('', 'Oral'), ('', 'Intramuscular; Intravenous'), ('', 'Oral'), ('20 mg', 'Parenteral'), ('', 'Oral'), ('', ''), ('20 mg / mL', 'Intramuscular; Intravenous; Subcutaneous'), ('', 'Intravenous'), ('', 'Oral'), ('', 'Intramuscular; Intravenous; Subcutaneous'), ('', 'Intramuscular; Intravenous'), ('20 mg', 'Intramuscular; Intravenous; Subcutaneous'), ('20 mg', 'Intramuscular; Intravenous'), ('20 mg', 'Intramuscular'), ('', 'Oral'), ('', 'Oral'), ('10 mg', 'Oral'), ('7.5 mg', 'Rectal'), ('', 'Oral'), ('', 'Oral'), ('', 'Intravenous'), ('20 mg/1ml', ''), ('10 mg', 'Oral'), ('5 mg/5ml', 'Oral'), ('10 mg', 'Oral'), ('10 mg', 'Oral'), ('5 mg/5ml', ''), ('10 mg', 'Oral'), ('5 mg/5ml', '')]\", \"properties\": \"[('logP', '0.79'), ('logS', '-5.3'), ('Water Solubility', '2.01e-03 g/l'), ('logP', '-1.9'), ('IUPAC Name', '(1R,2R,4S,5S,7R)-9-butyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-9-ium'), ('Traditional IUPAC Name', '(1R,2R,4S,5S,7R)-9-butyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-9-ium'), ('Molecular Weight', '360.473'), ('Monoisotopic Weight', '360.21693487'), ('SMILES', 'CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1'), ('Molecular Formula', 'C21H30NO4'), ('InChI', 'InChI=1S/C21H30NO4/c1-3-4-10-22(2)17-11-15(12-18(22)20-19(17)26-20)25-21(24)16(13-23)14-8-6-5-7-9-14/h5-9,15-20,23H,3-4,10-13H2,1-2H3/q+1/t15-,16-,17-,18+,19-,20+,22?/m1/s1'), ('InChIKey', 'YBCNXCRZPWQOBR-WVHCHWADSA-N'), ('Polar Surface Area (PSA)', '59.06'), ('Refractivity', '109.51'), ('Polarizability', '39.82'), ('Rotatable Bond Count', '8'), ('H Bond Acceptor Count', '3'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '15.15'), ('pKa (strongest basic)', '-2.7'), ('Physiological Charge', '1'), ('Number of Rings', '4'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '0'), ('MDDR-Like Rule', '1')]\", \"chEMBL\": \"3818\", \"pubChemCompound\": \"4798\", \"pubChemSubstance\": \"5195\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB13500\", \"fields\": {\"drugtype\": 1, \"name\": \"Otilonium\", \"groups\": \"37\", \"categories\": \"3215\", \"description\": \"None\", \"aliases\": \"Otilonium\", \"superclass\": \"9\", \"classname\": \"26\", \"subclass\": \"133\", \"direct_parent\": \"262\", \"indication\": \"None\", \"pharmacodynamics\": \"None\", \"moa\": \"None\", \"absorption\": \"None\", \"toxicity\": \"None\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('40 mg', 'Oral'), ('', ''), ('40 mg', 'Oral'), ('', 'Oral'), ('40 g', 'Oral'), ('', ''), ('40 mg', 'Oral'), ('', ''), ('', ''), ('', 'Oral'), ('', 'Oral'), ('', ''), ('', 'Oral')]\", \"properties\": \"[('logP', '2.92'), ('logS', '-7.3'), ('Water Solubility', '2.42e-05 g/l'), ('logP', '2.58'), ('IUPAC Name', 'diethyl(methyl)(2-{4-[2-(octyloxy)benzamido]benzoyloxy}ethyl)azanium'), ('Traditional IUPAC Name', 'diethyl(methyl)(2-{4-[2-(octyloxy)benzamido]benzoyloxy}ethyl)azanium'), ('Molecular Weight', '483.672'), ('Monoisotopic Weight', '483.321734293'), ('SMILES', 'CCCCCCCCOC1=CC=CC=C1C(=O)NC1=CC=C(C=C1)C(=O)OCC[N+](C)(CC)CC'), ('Molecular Formula', 'C29H43N2O4'), ('InChI', 'InChI=1S/C29H42N2O4/c1-5-8-9-10-11-14-22-34-27-16-13-12-15-26(27)28(32)30-25-19-17-24(18-20-25)29(33)35-23-21-31(4,6-2)7-3/h12-13,15-20H,5-11,14,21-23H2,1-4H3/p+1'), ('InChIKey', 'NQHNLNLJPDMBFN-UHFFFAOYSA-O'), ('Polar Surface Area (PSA)', '64.63'), ('Refractivity', '155.79'), ('Polarizability', '58.63'), ('Rotatable Bond Count', '17'), ('H Bond Acceptor Count', '3'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '12.75'), ('pKa (strongest basic)', '-3.9'), ('Physiological Charge', '1'), ('Number of Rings', '2'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '0'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"4201\", \"pubChemCompound\": \"0\", \"pubChemSubstance\": \"32\", \"Clinical_status\": 2}}, {\"model\": \"drug.drug\", \"pk\": \"DB13581\", \"fields\": {\"drugtype\": 1, \"name\": \"Rociverine\", \"groups\": \"7\", \"categories\": \"3222\", \"description\": \"None\", \"aliases\": \"Rociverine\", \"superclass\": \"8\", \"classname\": \"17\", \"subclass\": \"157\", \"direct_parent\": \"651\", \"indication\": \"None\", \"pharmacodynamics\": \"None\", \"moa\": \"None\", \"absorption\": \"None\", \"toxicity\": \"None\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('', ''), ('', 'Intramuscular; Intravenous'), ('', ''), ('', 'Oral'), ('20 mg', 'Intramuscular; Intravenous'), ('10 mg', 'Oral')]\", \"properties\": \"[('logP', '4.56'), ('logS', '-3.8'), ('Water Solubility', '5.82e-02 g/l'), ('logP', '3.99'), ('IUPAC Name', \\\"1-(diethylamino)propan-2-yl (1S,2S)-1-hydroxy-[1,1'-bi(cyclohexane)]-2-carboxylate\\\"), ('Traditional IUPAC Name', 'rilaten'), ('Molecular Weight', '339.52'), ('Monoisotopic Weight', '339.277344055'), ('SMILES', 'CCN(CC)CC(C)OC(=O)[C@H]1CCCC[C@]1(O)C1CCCCC1'), ('Molecular Formula', 'C20H37NO3'), ('InChI', 'InChI=1S/C20H37NO3/c1-4-21(5-2)15-16(3)24-19(22)18-13-9-10-14-20(18,23)17-11-7-6-8-12-17/h16-18,23H,4-15H2,1-3H3/t16?,18-,20+/m1/s1'), ('InChIKey', 'XPYLKZZOBVLVHB-QDKIRNHSSA-N'), ('Polar Surface Area (PSA)', '49.77'), ('Refractivity', '97.7'), ('Polarizability', '40.08'), ('Rotatable Bond Count', '8'), ('H Bond Acceptor Count', '3'), ('H Bond Donor Count', '1'), ('pKa (strongest acidic)', '14.09'), ('pKa (strongest basic)', '9.2'), ('Physiological Charge', '1'), ('Number of Rings', '2'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"8\", \"pubChemCompound\": \"0\", \"pubChemSubstance\": \"32\", \"Clinical_status\": 1}}, {\"model\": \"drug.drug\", \"pk\": \"DB13720\", \"fields\": {\"drugtype\": 1, \"name\": \"Diphemanil\", \"groups\": \"20\", \"categories\": \"3230\", \"description\": \"None\", \"aliases\": \"\\n      |Diphemanil\", \"superclass\": \"9\", \"classname\": \"26\", \"subclass\": \"38\", \"direct_parent\": \"74\", \"indication\": \"Used in the treatment of peptic ulcer, gastric hyperacidity, and hypermotility in gastritis and pylorospasm, and in the treatment of hyperhidrosis (excessive perspiration).\", \"pharmacodynamics\": \"Diphemanil Methylsulfate is a quaternary ammonium anticholinergic. It binds muscarinic acetycholine receptors and thereby decreases secretory excretion of stomach acids as well as saliva and sweat.\", \"moa\": \"Diphemanil Methylsulfate exerts its action by primarily binding the muscarinic M3 receptor. M3 receptors are located in the smooth muscles of the blood vessels, as well as in the lungs. This means they cause vasodilation and bronchoconstriction. They are also in the smooth muscles of the gastrointestinal tract (GIT), which help in increasing intestinal motility and dilating sphincters. The M3 receptors are also located in many glands which help to stimulate secretion in salivary glands and other glands of the body.\", \"absorption\": \"Poorly absorbed from the gastrointestinal tract with an absolute bioavailability of 15 to 25%.\", \"toxicity\": \"None\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[]\", \"properties\": \"[('logP', '-0.4'), ('logS', '-5.9'), ('Water Solubility', '3.72e-04 g/l'), ('logP', '-0.15'), ('IUPAC Name', '4-(diphenylmethylidene)-1,1-dimethylpiperidin-1-ium'), ('Traditional IUPAC Name', '4-(diphenylmethylidene)-1,1-dimethylpiperidin-1-ium'), ('Molecular Weight', '278.418'), ('Monoisotopic Weight', '278.190326197'), ('SMILES', 'C[N+]1(C)CCC(CC1)=C(C1=CC=CC=C1)C1=CC=CC=C1'), ('Molecular Formula', 'C20H24N'), ('InChI', 'InChI=1S/C20H24N/c1-21(2)15-13-19(14-16-21)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-12H,13-16H2,1-2H3/q+1'), ('InChIKey', 'LCTZPQRFOZKZNK-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '0'), ('Refractivity', '111.69'), ('Polarizability', '33.56'), ('Rotatable Bond Count', '2'), ('H Bond Acceptor Count', '0'), ('H Bond Donor Count', '0'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '0')]\", \"chEMBL\": \"4216\", \"pubChemCompound\": \"0\", \"pubChemSubstance\": \"32\", \"Clinical_status\": 3}}, {\"model\": \"drug.drug\", \"pk\": \"DB13835\", \"fields\": {\"drugtype\": 1, \"name\": \"Caroverine\", \"groups\": \"7\", \"categories\": \"3248\", \"description\": \"None\", \"aliases\": \"Caroverine\", \"superclass\": \"4\", \"classname\": \"49\", \"subclass\": \"60\", \"direct_parent\": \"214\", \"indication\": \"None\", \"pharmacodynamics\": \"None\", \"moa\": \"None\", \"absorption\": \"None\", \"toxicity\": \"None\", \"halflife\": \"None\", \"distribution_volume\": \"None\", \"protein_binding\": \"None\", \"dosages\": \"[('20 mg/ml', 'Intramuscular; Intravenous'), ('20 mg', 'Oral')]\", \"properties\": \"[('logP', '3.13'), ('logS', '-4.1'), ('Water Solubility', '3.00e-02 g/l'), ('logP', '3.5'), ('IUPAC Name', '1-[2-(diethylamino)ethyl]-3-[(4-methoxyphenyl)methyl]-1,2-dihydroquinoxalin-2-one'), ('Traditional IUPAC Name', 'caroverine'), ('Molecular Weight', '365.477'), ('Monoisotopic Weight', '365.210327121'), ('SMILES', 'CCN(CC)CCN1C(=O)C(CC2=CC=C(OC)C=C2)=NC2=CC=CC=C12'), ('Molecular Formula', 'C22H27N3O2'), ('InChI', 'InChI=1S/C22H27N3O2/c1-4-24(5-2)14-15-25-21-9-7-6-8-19(21)23-20(22(25)26)16-17-10-12-18(27-3)13-11-17/h6-13H,4-5,14-16H2,1-3H3'), ('InChIKey', 'MSPRUJDUTKRMLM-UHFFFAOYSA-N'), ('Polar Surface Area (PSA)', '45.14'), ('Refractivity', '110.77'), ('Polarizability', '41.44'), ('Rotatable Bond Count', '8'), ('H Bond Acceptor Count', '4'), ('H Bond Donor Count', '0'), ('pKa (strongest basic)', '8.68'), ('Physiological Charge', '1'), ('Number of Rings', '3'), ('Bioavailability', '1'), ('Rule of Five', '1'), ('Ghose Filter', '1'), ('MDDR-Like Rule', '1')]\", \"chEMBL\": \"4233\", \"pubChemCompound\": \"0\", \"pubChemSubstance\": \"32\", \"Clinical_status\": 1}}]"